

**Consensus proposal for Taxonomy and Definition of the
 Autoinflammatory Diseases (AIDs) - A Delphi Study**

Journal:	<i>Annals of the Rheumatic Diseases</i>
Manuscript ID	annrheumdis-2017-212515.R4
Article Type:	Criteria
Date Submitted by the Author:	n/a
Complete List of Authors:	Ben-Cherit, Eldad; Hadassah Hebrew University Medical Center, Rheumatology Unit Gattorno, Marco; Istituto Giannina Gaslini, UOSD Centro Malattie Autoinfiammatorie e Immunodeficienze Gul, Ahmet; Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology Kastner, Daniel; National Human Genome Research Institute, Inflammatory Disease Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch Lachmann, Helen; University College London Medical School, Centre for Amyloidosis & Acute Phase Proteins, Division of Medicine, Royal Free Campus Touitou, Isabelle; CHU Montpellier, Université de Montpellier, CEREMAIA, Centre de référence des maladies auto-inflammatoires rares et des amyloses, INSERM U11836 Ruperto, Nicolino; Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia - PRINTO
Keywords:	Autoimmune Diseases, Fever Syndromes, Familial Mediterranean Fever, Inflammation

SCHOLARONE™
 Manuscripts

Consensus proposal for Taxonomy and Definition of the Autoinflammatory Diseases (AIDs) - A Delphi Study

Eldad Ben-Chetrit¹, Marco Gattorno², Ahmet Gul³, Daniel L Kastner⁴, Helen J Lachmann⁵, Isabelle Touitou⁶ and Nicolino Ruperto⁷ for the Paediatric Rheumatology International Trials Organisation (PRINTO) and on behalf of the AIDs Delphi study participants*

Rheumatology Unit, Hadassah Hebrew University Medical Center¹, Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy², Department of Internal Medicine, Division of Rheumatology, Istanbul University Faculty of Medicine, Istanbul, Turkey³, Inflammatory Disease Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, US National Institutes of Health, Bethesda, Maryland, USA⁴, Centre for Amyloidosis & Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London Medical School, London, UK⁵, CEREMAIA, CHU Montpellier, Université de Montpellier, INSERM U1183⁶, Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia – PRINTO, Genoa, Italy⁷

*List of additional participants to the Delphi study

Ivona Aksentijevich, Bethesda, USA
Jordi Anton, Barcelona, Spain
Juan I Arostegui, Barcelona, Spain
Karyl S. Barron, Bethesda, USA
Luca Cantarini, Siena, Italy
Fatma Dedeoglu, Boston, MA, USA
Erkan Demirkaya, London, ON, Canada
Dirk Foell, Muenster, Germany
Joost Frenkel, Utrecht, Netherlands
Philip J. Hashkes, Jerusalem, Israel
Veronique Hentgen, Paris, France
Michael Hofer, Lausanne, Switzerland
Tilman Kallinich, Berlin, Germany
Isabelle Koné-Paut, Paris, France
Jasmin B. Kuemmerle-Deschner, Tuebingen, Germany
Ronald Laxer, Toronto, ON, Canada
Avi Livneh, Ramat Gan, Israel
Alberto Martini, Genoa, Italy
Laura Obici, Pavia, Italy

1
2
3 Seza Ozen, Ankara, Turkey
4 Dorota Rowczenio, London, United Kingdom
5 Ricardo Russo, Buenos Aires, Argentina
6 Yael Shinar, Tel Hashomer, Israel
7 Natasa Toplak, Ljubljana, Slovenia
8 Yosef Uziel, Kfar Saba, Israel
9 Marielle van Gijn, Utrecht, The Netherlands
10
11
12
13

14 Key words: Taxonomy, Autoinflammatory diseases, immune system
15
16
17

18 Short running title: Taxonomy and definition of AIDs
19
20
21
22
23
24

25 Corresponding author:
26

27 Eldad Ben-Chetrit, MD
28

29 Professor of Medicine (Rheumatology)
30

31 Rheumatology Unit
32

33 Hadassah-Hebrew University Medical Center
34

35 Jerusalem, Israel
36

37 POB: 12000
38

39 Tel: ++ 972-2-6777111
40

41 Fax: ++972-2-6777394
42

43 E-mail: eldad@hadassah.org.il
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background: Autoinflammatory diseases (AIDs) are a relatively new family of disorders defined about 19 years ago. Some of them are hereditary and some are not. The names given to these diseases do not follow any systematic guidelines and sometimes the same disorder carries several names.

Aims: The aim of this study is to refine the definition of the autoinflammatory diseases and to provide some conventions for their naming. We have focused our attention mainly on monogenetic AIDs.

Methods: Delphi technique which enables consensus among a group of experts through Internet and mail communication and questionnaires - was employed. After achieving 100% consensus among 6 members of a steering committee, the questionnaire containing the AID definitions and the agreed-upon conventions, were sent to 26 physicians and researchers working in the field of AIDs in order to gain broader support for the committee's proposals.

Results: The committee proposed the following definition for AIDs "Autoinflammatory diseases are clinical disorders caused by defect(s) or dysregulation of the innate immune system, characterized by recurrent or continuous inflammation (elevated acute phase reactants-APR) and the lack of a *primary* pathogenic role for the adaptive immune system (autoreactive T-cells or autoantibody production)". Several rules were defined for guiding the naming of these diseases among which are: abandoning eponyms and preferring the name of the gene over its encoded protein.

Conclusions: The new definition for AIDs allows inclusion of clinical disorders mainly associated with defects in the innate immune system. The new conventions propose names with clinical meaning and in some cases even clues for treatment.

1
2
3 Taxonomy is the science of naming. It is relevant to all fields of biology in which we
4 name plants, animals, objects and diseases. In medicine, naming of diseases or
5 syndromes has a special importance since it can give some clue about the nature of
6 the clinical condition, its clinical features, pathogenesis and sometimes even an
7 approach to treatment. Naming is also important for accurate and effective
8 communication among different health disciplines. However, medical disorders have
9 not been named in a standard way [1]. Physicians, who treat patients with a
10 particular disorder or face a new clinical condition, are often the first to propose a
11 name for the disease. Expert working groups may later revise the names to improve
12 their usefulness.
13
14
15
16
17

18 Names of medical disorders are often derived from one or a combination of the
19 following sources: genetic basis or biochemical defect; geographic spread; or by
20 eponyms. The main drawback of many names is the lack of a clinical meaning that
21 could help the novice to understand the origin of the disease or recognize its clinical
22 characteristics .
23
24
25

26 The autoinflammatory diseases (AIDs) are a group of medical disorders, derived from
27 defects or dysregulation of the innate immune system [2]. This family of diseases
28 was established in 1999 following the identification of the genes underlying two
29 recurrent fever syndromes: familial Mediterranean fever (FMF) [3,4] and TNF-
30 receptor-associated periodic syndrome (TRAPS) [5]. Over the last 18 years, more
31 and more diseases have been classified amongst this group of disorders, some of
32 which may not fit well with the classical definition of the AIDs. Moreover, many of
33 them were given names with no systematic guidelines or rules. In some cases, the
34 same disease carries several names (Table 1) [6-50]. This has led to a chaotic
35 situation in naming these clinical disorders and has called for a better standardization
36 of this field. This need is accentuated by recent progress in next generation
37 sequencing techniques (NGS), which have led to an increasing capability to identify
38 new genes and new syndromes, expanding the spectrum of AIDs.
39
40
41
42
43
44
45

46 Indeed, following the International Society for Systemic Autoinflammatory Diseases
47 (ISSAID) meeting in Lausanne, in 2013, a mandate was given to one of us (E B-C) to
48 undertake a preliminary consensus based exercise for the following aims: a. to refine
49 the definition of the "autoinflammatory diseases". b. to provide some rules and new
50 proposals for naming this current group of clinical conditions and those that will be
51 identified in the future.
52
53
54
55
56
57
58
59
60

Methods

In order to find the different definitions proposed for AIDs over the years, we searched the MEDLINE/PubMed Central® (PMC) from 1998 to January 2016, using the MESH search term: “autoinflammatory diseases” (supplementary Figure S1). In order to find the names used for each AID, we took one of their current names as depicted in Table 1 and searched for papers where they were first reported. Then, we searched for reviews on these items to find additional synonymous names Table 1 is based on a list of AIDs published by one of the authors (IT) [51], properly integrated and updated during the consensus process and finally approved by all the steering committee members. It focused - mainly - on monogenic disorders.

For choosing the best definition for AIDs and the most appropriate name for each AID, we have used the Delphi technique, which enables consensus among a group of experts through mail communication [52]. The Delphi method is essentially a series of questionnaires involving several steps, each of which is based on the results of the previous step. The process stops when consensus of at least 80% of the participants on each item is reached. [53]

An *ad hoc* steering committee of 6 clinicians and researchers from 6 different countries who are working in the field of autoinflammation was established.

The first Delphi questionnaire was built through sending broad and open-ended questions in order to elicit different opinions from the panelists about the current definitions and names of AIDs.

Once received, the replies from the panelists were analyzed to generate a series of statements that were employed as the basis for follow up questionnaires that were sent back to the individual participants. In each subsequent questionnaire, the panelists were also provided with the overall results (responses) of the previous questionnaire from all the members. After achieving 100% consensus among the steering committee members, the questionnaire containing the AID definitions and the agreed-upon names of AIDs were sent to 26 physicians and researchers working in the field of AIDs around the world. They were identified in the Paediatric Rheumatology International Trials Organization (PRINTO) mailing list through their high active participation in the Eurofever registry [54, 55]. The aim of this step was to gain broader support for the committee's proposals and to consider changes once a name was rejected by or was not acceptable to more than 80% of the participants of the large group of AIDs experts. Delphi survey implementation was conducted by PRINTO [56].

Results

AIDs proposed definition

The literature review disclosed 536 papers of which only 7 specifically dealt with the definitions of AIDs [5, 57- 62] (supplementary Figure S1). The first definition for AIDs was proposed by the NIH group in 1999 [5]. This definition was as follows: "The autoinflammatory syndromes are systemic disorders characterized by apparently unprovoked inflammation in the absence of high-titer autoantibodies or antigen-specific T lymphocytes". This definition was based mainly upon the two diseases whose related genes had then been identified: FMF and TRAPS [3- 5]. Since in both diseases the flares appeared mostly spontaneous, the definition included the word "unprovoked". The definition stresses the lack of involvement of the adaptive immune system in these disorders, since no autoantibodies or autoreactive T-cells were involved.

Seven years later McGonagle and McDermott suggested another definition: "AIDs are characterized by self-directed inflammation, whereby local factors at sites predisposed to disease lead to activation of innate immune cells, including macrophages and neutrophils, with resultant target tissue damage. For example, disturbed homeostasis of canonical cytokine cascades (as in the periodic fevers), aberrant bacterial sensing (as in Crohn's disease), and tissue micro-damage predispose one to site-specific inflammation that is independent of adaptive immune responses" [57]. The authors proposed that immunological diseases ought to be conceived as a continuum with "pure monogenic autoinflammatory diseases" at one end and "pure monogenic autoimmune diseases" at the other. This definition is relatively complex, but explicitly invokes innate immunity and widens the spectrum of AIDs.

Later, several other definition or refinement were proposed [58-61]. In a recent study, de Jesus et al. provide an outstanding classification of AIDs strictly based on their pathophysiology [62]. However, the authors do not propose a new definition for the AIDs.

Given the proliferation of AID definitions, with sometimes conflicting concepts, the steering committee agreed to adopt the first and original definition with minor modifications: "Autoinflammatory diseases are clinical disorders caused by defect(s) or dysregulation of the innate immune system, characterized by recurrent or

1
2
3 continuous inflammation (elevated - APR) and the lack of a *primary* pathogenic role
4 for the adaptive immune system (autoreactive T-cells or autoantibody production).”
5

6 This definition emphasizes the essential fact that the disorders are caused by defects
7 in the innate immune system and are continuous or recurrent. The word
8 "unprovoked" has been deleted since in many cases there is a trigger for the acute
9 flares.
10
11

12
13 The steering committee is aware that diseases such as PLCG2-associated antibody
14 deficiency and immune dysregulation (PLAID) or Heme - oxidised IRP2 ubiquitin
15 ligase1 (HOIL-1) deficiency, traditionally included among the AIDs, will not be part of
16 this group, because they may contain components of the adaptive immune system
17 such as autoantibodies [63]. The "Interferonopathies" include some disorders also
18 manifesting autoantibodies. However, the consensus seemed to be that for disorders
19 like Aicardi-Goutières Syndrome (AGS) in which nucleic acid sensing is primarily
20 intracellular, autoantibodies usually play a minor role in disease pathogenesis, and
21 thus the autoinflammatory designation may still be appropriate. In their recent review
22 Rodero and Crow propose that "type I interferonopathies can reasonably be
23 considered as autoinflammatory in origin, with 'spill-over' into autoimmunity in some
24 cases" [64]. The group of "typical" **autoimmune diseases** includes disorders
25 affecting primarily or only the adaptive system such as systemic lupus erythematosus
26 (SLE), Hashimoto thyroiditis, DNase deficiencies and autoimmune
27 lymphoproliferative syndrome (ALPS).
28
29
30
31
32
33
34
35

36 **AIDs proposed nomenclature**

37
38 The current names for AIDs bring several problems and issues, which called for a
39 new approach and nomenclature modification; many AIDs possess more than a
40 single name (FMF - 7 different names, TRAPS - 3, etc) (Table 1 and Supplementary
41 Table S1); different clinical presentations are associated with similar sequence
42 alterations in the same gene eg. Muckle-Wells syndrome(MWS), familial cold
43 autoinflammatory syndrome (FCAS) and Neonatal onset multisystem inflammatory
44 disease (NOMID) are associated with *NLRP3* gene whereas FMF and pyrin-
45 associated autoinflammation with neutrophilic dermatosis (PAAND) are associated
46 with *MEFV* gene. In addition discussion arose about several topics briefly
47 summarized herein: In naming AIDs should we use the name of the gene or that of
48 the encoded protein (*MEFV* or pyrin)? Should we include typical clinical features or
49 just genetic attributes? Should historical names be retained?
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Following more than 6 cycles of Delphi questionnaires and oral discussions among
4 the 6 members of the steering committee with further involvement of the 26 AIDs
5 experts around the world - a consensus of at least 80% was reached for the
6 nomenclature of the diseases shown in Tables 1 and 2.
7
8

9 **General conventions (Table 3)**

10
11 The proposed names for AIDs have been established according to the rules and
12 suggestions outlined in Table 3.
13
14

15 In many diseases the course of the disease is episodic with frequent attacks and
16 attack-free intervals. When the frequency of the attacks is relatively regular (as is the
17 case with Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) and
18 sometimes with mevalonate kinase deficiency (MKD) we preferred the term
19 "periodic". When the attacks do not have a regular pattern, we suggested the word
20 "recurrent".
21
22
23
24

25 In the past, both terms, "periodic" and "recurrent", have been used interchangeably
26 but now the term "periodic" remained in the names of 3 conditions only; Cryopyrin-
27 associated periodic fever syndrome (CAPS), TRAPS and PFAPA. In TRAPS, we
28 decided to keep the original name "periodic", although its flares are recurrent rather
29 than periodic. In CAPS, we propose a new name (NLRP3-AID) which does not
30 contain the word "periodic since the attacks are not periodic". Thus, we strongly
31 suggest using the more appropriate terms in naming disorders in the future.
32
33
34
35

36 As a general rule, we tried to use names containing etio-pathological (genetic)
37 features of the disease and where appropriate or possible, to add a significant clinical
38 characteristic of the syndrome. Thus, we left the name TRAPS without change, since
39 it consists of its genetic etiology (mutations in *TNFRSF1A* gene) and characteristic
40 clinical features [periodic (recurrent) fever]. On the other hand, the name hyper IgD
41 syndrome (HIDS) was abandoned since it is an absolutely inaccurate name: serum
42 IgD is not always elevated in these patients while it may be elevated in other AIDs.
43 Therefore, this name was replaced by MKD based upon our knowledge of the gene
44 involved, mevalonate kinase (*MVK*). In this way, a physician or researcher who
45 approaches these names for the first time may have immediately a basic
46 understanding of the disorder and sometimes even a clue to the potential treatment.
47
48
49
50
51
52

53 In cases where the choice was between using the name of the gene associated with
54 the disease or the protein encoded by the gene, we preferred the name of the gene
55
56
57
58
59
60

1
2
3 over that of the protein unless the former was meaningless. A typical example is the
4 choice of *NLRP3* gene over cryopyrin despite the tendency of some clinicians to stay
5 with the former term CAPS. Fortunately, in many cases the name of the gene and the
6 encoded protein are the same (MK, NOD2) making the choice easier. However, this
7 was not the case with the *MEFV* gene and pyrin where the name of the protein was
8 chosen, as will be discussed later.
9

10
11
12 In our proposals for new taxonomy of AIDs, we tried to avoid the use of names of
13 persons (such as Nakajo Nishimura syndrome) or geographical distribution of the
14 disease (such as Guadeloupe fever) or names with unusual meaning (such as
15 "Cherubism").
16
17

18 19 **Specific names (Table 1 and Supplementary Table S1)**

20
21 In the case of CAPS – which encompasses three clinical entities (FCAS, MWS,
22 NOMID/CINCA), the committee has proposed using a single name; *NLRP3*-
23 associated autoinflammatory disease (*NLRP3*-AID). Since the various disorders
24 reflect different levels of phenotypic severity of the same disease, it was suggested to
25 add the adjectives: mild, moderate, and severe phenotypes, instead of using the
26 historical names FCAS, MWS and CINCA/NOMID, respectively.
27
28

29
30
31 In familial cold autoinflammatory syndrome 2 (FCAS2) (Guadeloupe fever), different
32 families present with different phenotypes [36]. Since the gene associated with the
33 disease (*NLRP12*) is known, the committee decided to name this syndrome *NLRP12*-
34 associated autoinflammatory disease (*NLRP12*-AID).
35
36

37
38 In the case of *MEFV*-associated diseases, the question raised was as follows: should
39 we use the old name FMF or "atypical FMF" for all syndromes associated with
40 mutations in the *MEFV* gene even if they have totally different clinical
41 manifestations? Alternatively, should we find a different way to classify these
42 disorders? The committee chose to use a general name (as a "roof ") "pyrin-
43 associated autoinflammatory diseases" (PAAD) which includes all diseases
44 associated with pyrin defects or *MEFV* mutations. Under this general term, there are
45 subtypes of disorders with different names, according to their clinical presentation or
46 genetic features, such as: PAAND, FMF, etc. [65] (Figure 1). Although it is preferred
47 using the name of the gene over the name of the encoded protein, in the case of
48 FMF, the protein pyrin was chosen rather than the *MEFV* gene. One of the reasons
49 was that the name *MEFV*, which was coined to denote its association with familial
50 **Mediterranean fever**, is no longer accurate, since it may lead to totally different AIDs,
51
52
53
54
55
56
57

1
2
3 such as PAAND and CRMO-like disorder. In addition, we did not change the name of
4 familial Mediterranean fever (FMF), although sometimes it is neither familial nor
5 restricted to the Mediterranean basin and in rare cases, it may even be without a
6 documented fever. Most members of the steering committee thought that FMF is a
7 well-known and defined entity and that changing the name would cause discomfort
8 and confusion among the AID clinical community. The name FMF remained under
9 the "roof" of "pyrin-associated autoinflammatory diseases" (PAAD) as a clinical entity
10 which is restricted mainly to Middle Eastern patients or to patients elsewhere, whose
11 disease is associated with exon 10 mutations [66].
12
13
14
15

16
17 Regarding Mevalonate kinase disorders the committee suggested leaving MKD as a
18 general name with the option of adding "mild" for those with hyper IgD syndrome and
19 "severe" for those with mevalonic aciduria (67). In rare cases, where the patient with
20 MKD has also retinitis pigmentosa or prokeratosis, it is suggested to mention these
21 manifestations in addition to MKD (Table 1, and Supplementary Table S1).
22
23
24

25 The name *NOD2*-associated granulomatous disease was chosen by the committee
26 for the three phenotypes: Blau syndrome, familial sarcoidosis and familial Crohn's
27 disease. Since all these syndromes are characterized by granulomas, this feature
28 was included in the name. Nevertheless, an option was offered to add IBD in cases
29 where the intestines are the main site of involvement eg. *NOD2*-associated
30 granulomatous IBD (formerly called familial Crohn's disease).
31
32
33
34

35 The name for CRMO was replaced by the name chronic non-bacterial osteomyelitis
36 CNO. The reason for that was the presence of many cases where the disease was
37 neither recurrent nor multifocal. Furthermore, the new name emphasizes the main
38 feature of the disease, non-bacterial osteomyelitis. Since this clinical entity may be
39 associated with mutations in various genes, it is optional to add the name of the gene
40 when it is known. For example in case the gene involved is *LPIN2* it can be marked
41 as *LPIN2*-CNO (previously known as Majeed's syndrome). In adults, patients with
42 sporadic CNO are usually diagnosed with SAPHO, a symptom complex of Synovitis,
43 Acne, Pustulosis, Hyperostosis, and Osteitis [68].
44
45
46
47
48

49 Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature
50 syndrome (CANDLE syndrome) gained a new name: *PSMB8*-PRAAS - where
51 *PSMB8* stands for Proteasome Subunit Beta 8 and PRAAS for PRoteasome-
52 Associated Autoinflammatory Syndrome. This name replaces also the eponym
53 Nakajo Nishimura syndrome, and JMP which stands for Joint contractures, Muscle
54 atrophy, microcytic anemia and Panniculitis-induced lipodystrophy. The name
55
56
57
58
59
60

1
2
3 *PSMB8*-PRAAS consists of the genetic etio-pathology of the disorder but does not
4 include any clinical feature of the disease.
5

6 *CARD14*-associated disease is usually characterized by psoriasis with or without
7 pustulosis. Therefore, the name was refined to be *CARD14*-associated psoriasis.
8
9

10 Since the 3 variants of IL-10 deficiency are always associated with inflammatory
11 bowel disease, the committee proposed a single name as IL-10 deficiency-
12 associated IBD.
13
14

15 The names; deficiency of the interleukin 1 receptor antagonist (DIRA), deficiency of
16 the interleukin 36 receptor antagonist (DITRA), pyogenic arthritis, pyoderma
17 gangrenosum, and acne (PAPA) and PFAPA remained unchanged since they
18 already conform to our naming conventions. However, the letter P in the abbreviation
19 "PAPA" now stands for the name of the gene *PSTPIP1* rather than "Pyogenic" and,
20 therefore, the new name is "*PSTPIP1*-associated arthritis, pyoderma gangrenosum
21 and acne" (PAPA).
22
23
24
25

26 The name "Cherubism" was derived from the Biblical "cherub" (plural cherubim) who
27 has four faces of different species and several pairs of wings,. For most physicians
28 this name does not mean much and therefore, the committee proposed the name
29 *SH3BP2* deficiency with multilocular cystic disease of the mandibles (SDCM). This
30 name gives the etio-pathologic basis of the syndrome with the main clinical feature of
31 fibrous dysplasia of the mandibles.
32
33
34
35

36 Finally, the name "Schnitzler syndrome" also remained as an historical one, since its
37 pathogenesis is still obscure and its relationship with *NLRP3* mutations has not been
38 established [69]. A proposal to convert the name of the syndrome to a clinical
39 description: "late onset gammopathy with recurrent urticaria and fever" (LOGRUF)
40 did not gain support from most of the committee members.
41
42
43
44

45 **Discussion**

46 The definition of autoinflammatory diseases has changed over the years in order to
47 accommodate the new diseases discovered since 1999 – the year the term was first
48 proposed [2, 5, 57-61]. Widening the scope and spectrum of definition of AIDs
49 resulted in the inclusion of disorders with additional defects in the adaptive immune
50 system such as PLAID or HOIL-1 deficiency. Most defects in the immune system
51 may affect primarily either the innate or the adaptive arm. However, it is becoming
52 increasingly obvious that the innate immune system almost always has an effect on
53
54
55
56
57

1
2
3 the adaptive system. This leads to the situation that there are disorders that do not fit
4 neatly into the "pure" autoinflammatory or autoimmune categories, and reside
5 actually in a "grey zone" between these two groups. In order to include these
6 disorders with the typical AIDs under the same "rafter", Peckham et al. offered the
7 term "Auto-inflammatory-immune diseases" [70]. We believe that this new name may
8 lead to confusion since all the disorders caused or related to defects in the immune
9 system can be classified under this wide term with no clear categorization. The
10 interferonopathies are clinical disorders caused by defects in the innate response,
11 leading to inflammation after DNA sensing. The activation of cells of the adaptive
12 immunity is a secondary effect of this condition and seems to play a minor role in
13 their pathogenesis. Therefore, they may create the bridge which fits the concept that
14 the autoinflammatory diseases, and the autoimmune diseases are actually in the
15 same spectrum of immune disorders. This continuum model is further supported by
16 the recent discovery of the innate lymphoid cells (ILCs). These cells are defined by
17 differential expression of cell-surface markers and are activated by neuropeptides,
18 cytokines and other alarmins [71]. Their specialized distribution in lymphoid and non-
19 lymphoid tissues, coupled with their functional heterogeneity, has provoked a
20 fundamental reassessment of how they integrate innate and adaptive immune
21 responses.

22
23
24
25
26
27
28
29
30
31
32 As already mentioned - many of the current names of AIDs were not appropriate,
33 inaccurate or lack any clinical meaning. Therefore, an attempt to establish new
34 conventions for naming them was really needed.

35
36
37 The conventions (Table 3), and the ensuing proposals (Table 1, and Supplementary
38 Table S1), call for using the name of the gene associated with the disease when it is
39 known rather than the encoded protein. In these cases, demonstration of functional
40 significance of the identified sequence alteration is mandatory. The main advantage
41 of using the name of the gene is that such a name gives the physician a clue about
42 the pathogenesis of the disease and sometimes even about a potential treatment.
43 Moreover, it may allow definite diagnosis using genetic testing. However, it should be
44 borne in mind that including the gene in the name of the disease may pose a problem
45 in cases where the clinical features of the patient are compatible with a certain
46 diagnosis while no expected sequence alteration is found. Thus, the main drawback
47 of using the name of the gene is that **definite** diagnosis can be made only by genetic
48 testing.

1
2
3 In cases where the clinical features and the genetic testing results are in accord, the
4 name is appropriate and the diagnosis is correct and definite. When there is a clearly
5 pathogenic mutation but the clinical features are completely incompatible with the
6 expected diagnosis, one should consider a different disease with a different name.
7 This situation is illustrated by the case of the *MEFV* mutation S242R, which causes
8 neutrophilic dermatosis. The name of this disease is not "FMF" or "atypical FMF"
9 despite the fact that there are *MEFV* mutations - but "pyrin-associated
10 autoinflammation with neutrophilic dermatosis (PAAND)". Similar approach may be
11 applied in the case of *PSTPIP1* with the new mutation and different clinical
12 presentation [72]. We suggest here a "roof" name : *PSTPIP1*-associated
13 autoinflammatory diseases with two subtypes: PAPA and PAMI (*PSTPIP1*-
14 associated myeloid-related proteinemia inflammatory syndrome). However, we
15 cannot add this approach to Table 1 since it was not discussed in the Delphi
16 questionnaires among the large group of participants
17
18
19
20
21
22
23

24 When the clinical features are typical for a certain disease (for example FMF) and
25 yet no genetic support for this diagnosis is found, one can denote this medical
26 condition as an FMF-like disease. However, a better choice would be to leave the
27 case as an undefined AID until mutations in other genes are found or additional
28 explanations for the disease are given. The reason is that clinical features typical for
29 one AID may be associated with mutations in different genes. For example, in
30 arecent report, Karacan et al. described two Turkish families in whom 4 patients
31 presented with typical clinical features of FMF [73]. Genetic analysis performed in
32 these patients failed to show *MEFV* mutations. However, total exon sequencing
33 revealed that two patients were homozygous for mutations in *MVK* and the two other
34 patients carried mutations in the *TNFRSF1A* gene. These cases illustrate the
35 difficulties in making a diagnosis of AID based upon clinical features only and justify
36 the proposal to use the gene in naming AIDs wherever it is known.
37
38
39
40
41
42
43

44 The way we proposed naming CAPS and FCAS 2 namely NLRP3-associated
45 autoinflammatory disease (NLRP3-AID) and *NLRP12*-AID respectively may pave the
46 way for naming future disorders to be discovered or identified among the other
47 members of the large family of NOD-like receptors (NLRs).. Similarly, *PSMB8*-
48 PRAAS, the name which was proposed to replace CANDLE syndrome, JMP and
49 NNS, may also serve as an example for naming additional proteasome associated
50 diseases to be discovered, just by changing their number. In fact, Brehm et al.
51 recently described several cases that carry mutations in *PSMA3* (encodes $\alpha 7$),
52
53
54
55
56
57
58
59
60

1
2
3 *PSMB4* (encodes $\beta 7$), *PSMB9* (encodes $\beta 1i$), and proteasome maturation protein
4 (*POMP*) [74].
5

6
7 Unfortunately, the current study did not include many other monogenic AIDs such as
8 those associated with *ADA2*, *NLRC4*, *NLRP1* genes or X-linked inhibitor of apoptosis
9 (*XIAP*) deficiency and (SLAM)-associated protein (*SAP*) deficiency (75). The reason
10 is that we limited ourselves mainly to the basic list reported by Toiutou et al.(51).
11 However, we hope that the conventions we propose herein may help modifying
12 names of additional diseases - old and new – when, they do not follow the rules
13 suggested.
14
15

16
17
18 For this project we used the Delphi technique which allowed discussion via an *ad hoc*
19 web-based system developed by the PRINTO staff under the supervision of NR who
20 has an extensive expertise in consensus formation methodologies. The PRINTO
21 system allowed remote interaction between the participants who had the possibility to
22 share written comments with the other participants in a transparent and traceable
23 way. A limitation of the current work was that for lack of funding we could not conduct
24 a formal nominal group technique (NGT) which is a guided face-to-face discussion
25 and interaction, among small groups of experts. However, the additional discussion
26 of the *ad hoc* steering committee consensus proposal by another group of 26
27 worldwide experts in the field of AIDs further strengthens these proposals.
28
29
30
31

32
33 In conclusion, the currently proposed rules for nomenclatures of AIDs are expected
34 to allow a better organization of these groups of immune diseases. However,
35 taxonomy is a dynamic process and some of the proposed names may be changed
36 in the future as we gain a better knowledge about their pathogenesis. The proposed
37 taxonomy may gain a broader consensus following an effective communication with
38 other societies such as the International Union of Immunological Societies Expert
39 Committee (IUIS).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank the staff from the PRINTO office (Eugenia Mosci, Luca Villa, and Roberto Cavanna).

Contributorship Statement

All authors (EBC, MG, AG, DLK, HJL, IT, NR) contributed equally to the planning and conduct of the study. Their placement in the authors' list is dictated by the alphabetic order of their family names.

The first version of the present manuscript was written by EBC, MG and NR, and then revised critically by all the remaining co-authors (AG, DLK, HJL, IT).

Funding

The development and coordination of the Delphi survey has been funded with the research budgets of Istituto Giannina Gaslini; no external entity such as pharmaceutical companies has been involved at any stage of the project.

Competing interests

Authors:

For EBC, MG, AG, DLK, HJL, IT: Nothing to disclose for this manuscript.

NR received honoraria for consultancy of speaker's bureau from the following pharmaceutical companies since last 5 years: Abbott, AbbVie, Amgen, Biogenidec, Astellas, Alter, AstraZeneca, Baxalta Biosimilars, Boehringer, BMS, CD-Pharma, Celgene, CrescendoBio, EMD Serono, Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, Rewind Arms, R-Pharma, Sanofi Aventis, Servier, Sinergie, Takeda, Vertex, UCB Biosciences GmbH.

The Gaslini Hospital, which is the public Hospital where NR works as full time public employee, has received contributions from the following industries:

Abbott, BMS, "Francesco Angelini", GlaxoSmithKline (GSK), Hoffman-La Roche, Italfarmaco, Janssen, Novartis, Pfizer, Sanofi Aventis, Schwarz Biosciences, Sobi,

1
2
3 Xoma, Wyeth. This money has been reinvested for the research activities of the
4 hospital in a fully independent manner without any commitment with third parties.
5
6
7

8 **Additional participants to the Delphi study**

9

10 Ivona Aksentijevich, Jordi Anton, Juan I Arostegui, Karyl S. Barron, Luca Cantarini,
11 Fatma Dedeoglu, Erkan Demirkaya, Joost Frenkel, Veronique Hentgen, Michael
12 Hofer, Isabelle Koné-Paut, Jasmin B. Kuemmerle-Deschner, Avi Livneh, Alberto
13 Martini, Laura Obici, Seza Ozen, Dorota Rowczenio, Ricardo Russo, Yael Shinar,
14 Natasa Toplak, Marielle van Gijn have no conflicts of interest to declare.
15

16 Dirk Foell has received grant support from Novartis and Pfizer, and honoraria from
17 Sobi, Chugai-Roche, Novartis and Pfizer

18 Philip J. Hashkes has acted as consultant and speaker for Novartis and consultant
19 for Neovii.
20

21 Yosef Uziel has received Grant / Research Support from Novartis, has acted as
22 consultant for Novartis, and has received speaker's bureau from Abbvie, Neopharm,
23 Novartis and Roche.

24 Tilmann Kallinich has received speaker's bureau from Novartis, Sobi and Roche, and
25 a research grant from Novartis.
26

27 Ronald Laxer has acted as consultant for Lilly and Sanofi
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Beil M, Ben-Chetrit E. Taxonomy of auto-inflammatory diseases: time to consider changing some names. *Clin Exp Rheumatol* 2013;31(3 Suppl 77):3-5.
2. Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. *Nat Immunol* 2017; 18: 832– 842 .
3. International FMF Consortium: Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. *Cell* 1997; 90:797-807.
4. French FMF Consortium: A candidate gene for familial Mediterranean fever. *Nat Genet* 1997;17:25-31.
5. McDermott M F, Aksentijevich I, Galon J, et al. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes *Cell* 1999;97: 133 –144
6. Siegal S (1945). "Benign paroxysmal peritonitis". *Ann Intern Med* 1945; 23 (2): 234 – 247
7. Reiman HA . "Periodic disease. Probable syndrome including periodic fever, benign paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia". *J Am Med Assoc* 1948; 136 (4): 239 – 244.
8. Cattan R, Mamou H. 14 Cases of periodic disease, 8 of which are complicated by kidney diseases. *Bull Mem Soc Med Hop Paris*. 1951;67:1104–1110
9. Heller H, Sohar E, Sherf L. Familial Mediterranean fever. *AMA Arch Intern Med* 1958;102:50 – 71
10. Ehrenfeld E N, Eliakim M, Rachmilewitz M, Recurrent polyserositis (familial mediterranean fever; Periodic disease): A report of fifty-five cases. *The Am Journal of Med* 1961; 3: 107-123
11. Saatci U, Ozen S, Bakkaloglu A, et al.Familial Mediterranean fever: a misnomer? *Lancet*. 1994;343(8895):485.
12. Masters SL, Lagou V , Jéru I et al. Pypin Associated Autoinflammation with Neutrophilic Dermatitis (PAAND), Familial autoinflammation with neutrophilic dermatitis reveals a regulatory mechanism of pypin activation. *Science Translational Medicine* 2016; 8 : 332-345
13. Williamson L M, Hull D, Mehta R, et al. Familial hibernian fever. *Quart J Med*, 1982, 51; 469 –480

14. Mulley J, Saar K, Hewitt G et al.. Gene localization for an autosomal dominant familial periodic fever to 12p13 *Am J Hum Genet* 1998; 62: 884–889
15. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. *Nat Genet* 1999; 22 : 178 – 181.
16. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. *Nat Genet* 1999; 22 (2): 175 –177.
17. van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. *Lancet* 1984; 1 (8386): 1087–1090.
18. Frenkel J, Houten SM, Waterham HR et al. Mevalonate kinase deficiency and Dutch type periodic fever. *Clin Exp Rheumatol* 2000;18(4):525-532
19. Prieur AM, Griscelli C Arthropathy with rash, chronic meningitis, neurological changes and arthritis. *J Pediatr* 1981; 99: 79-83.
20. Muckle TJ. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. *Quart J Med*. 1962 ; 31: 235 – 248
21. Kile, R. L., Rusk, H. A. A case of cold urticaria with unusual family history. *J Am Med Assoc* 1940; 114: 1067-1068
22. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat Genet* 2001; 29 (3): 301–305
23. Blau EB. Familial granulomatous arthritis, iritis, and rash. *Pediatr*. 1985;107(5):689 - 693
24. James DG. A comparison of Blau's syndrome and sarcoidosis. *Sarcoidosis* 1994;11(2):100-1
25. McGovern DP, van Heel DA, Ahmad T, et al. NOD2 (CARD15), the first susceptibility gene for Crohn's disease. *Gut*. 2001;49:752–754.
26. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1–receptor antagonist. *N Engl J Med* 2009; 360: 2426–2437.
27. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. *N Engl J Med* 2011;365 (7):620–628
28. Majeed, H; Kalaawi, M; Mohanty, D et al. Congenital dyserythropoietic anemia and chronic recurrent multifocal

- osteomyelitis in three related children and the association with Sweet syndrome in two siblings. *J Pediatrics* 1989;115: 730 – 734.
29. Ferguson P J, Chen S, Tayeh M K, et al.. Homozygous mutations in *LPIN2* are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome) *J Med Genet* 2005;42:551–557.
30. Keipert JA, Campbell PE. Recurrent hyperostosis of the clavicles: an undiagnosed syndrome. *Aust Paediatr J* 1970; 6 (1):97–104.
31. Giedion A, Holthusen W, Masel LF, et al. Subacute and chronic “symmetrical” osteomyelitis. *Ann Radiol (Paris)* 1972;15(3):329 – 342
32. Fuchs-Telem D, Sarig O, van Steensel M A M et al. Familial Pityriasis Rubra Pilaris Is Caused by Mutations in *CARD14* *Am J Hum Genet* 2012 ;91: 163–170
33. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in *CARD14*. *Am J Hum Genet* 2012;90:784-795
34. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med*. 2009;361(21):2033 – 2045.
35. Glocker EO, Frede N, Perro M, et al. Infant colitis-it’s in the genes. *Lancet*. 2010;376 (9748):1272
36. Jeru I, Duquesnoy P, Fernandes-Alnemri T et al. Mutations in *NALP12* cause hereditary periodic fever syndromes. *PNAS*, 2008 :105 (5): 1614 –1619
37. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. *Mayo Clin Proc* 1997;72:611–615
38. Wise CA, Gillum JD, Seidman CE, et al. Mutations in *CD2BP1* disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. *Hum. Mol. Genet*. 2002;11:961–969
39. Liu Y, Ramot Y, Torrelo A et al: Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. *Arthritis Rheum*. 2012; 64: 895-907
40. Agarwal AK, Xing C, DeMartino GN et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. *Am J Hum Genet* 2010; 87: 866-872
41. Arima K, Kinoshita A, Mishima H, et al: Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. *Proc Natl Acad Sci U S A*. 2011, 108: 14914 - 14919

42. Schnitzler L. Lésions urticariennes chroniques permanentes (érythème pétaoloïde?) Cas cliniques No 46 B, *J Dermatol Angers* 1972 ; Abstract 46
43. Tyson T K, Edwards F L. Periodic fever syndrome in children. *J Pediatr* 1999; 135: 1– 5
44. Marshall GS, Edwards KM, Butler J, et al. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. *J Pediatr* 1987;110:43 - 46
45. Ombrello M J, , Remmers E F, Sun G et al. Cold Urticaria, Immunodeficiency, and Autoimmunity Related to *PLCG2* Deletions *N Engl J Med* 2012; 366:330-338
46. Wang K, Kim C, Bradfield J, et al. Whole-genome DNA/RNA sequencing identifies truncating mutations in *RBCK1* in a novel Mendelian disease with neuromuscular and cardiac involvement. *Genome Medicine* 2013; 5 (7): 67-74
47. Ueki Y, Tiziani V, Santanna C. et al. Mutations in the gene encoding c-Abl-binding protein *SH3BP2* cause cherubism. *Nat Genet*2001;28:125 –126
48. Jones, W. A. Familial Multilocular Cystic Disease of the Jaws. *American J Cancer* 1933;17 (4): 946-950
49. Jones, W. A. Gerrie, J. Pritchard, J. Cherubism-familial fibrous dysplasia of the jaws. *J bone joint surgery*1950;32 (3): 334–347.
50. Jaffe H L. Giant cell reparative granuloma traumatic bone cyst, fibrous (fibro-osseous) dysplasia of jaw bones. *Oral Surg* 1953;6:159-175
51. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigms and nomenclature. *J Med Genet* 2013;50:349–359
52. Ruperto N, Meiorin S, Iusan S M, et al. Consensus procedures and their role in pediatric rheumatology. *Curr rheumatol reports* 2008;10:142-146.
53. Pill J, The Delphi method: Substance, context, a critique and an annotated bibliography. *Socio-Economic Planning Sciences*. 1971; 5: 57-71
54. Toplak N, Frenkel J, Ozen S et al. for the Paediatric Rheumatology International Trials Organisation (PRINTO). Eurotraps and Eurofever Projects. An International registry on Autoinflammatory diseases: the Eurofever experience. *Ann Rheum Dis* 2012;71:1177-1182.
55. Federici S, Sormani M, Ozen S et al for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project. Evidence-based provisional clinical classification criteria for

- 1
2
3 autoinflammatory periodic fevers. *Ann Rheum Dis* 2015; 2015;74:799
4 – 805
5
6 56. Ruperto N, Martini A, for the Paediatric Rheumatology International
7 Trials Organisation (PRINTO). Networking in pediatrics: the example
8 of the Pediatric Rheumatology International Trials Organisation
9 (PRINTO). *Archives Dis Child* 2011; 96:596 - 601.
10
11
12 57. McGonagle D, McDermott MF (2006) A proposed classification of the
13 immunological diseases. *PLoS Med* 2006; 3 (8): e297:1242-1248
14
15 58. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory
16 disease reloaded: a clinical perspective. *Cell* 2010;140:784–790.
17
18 59. Grateau G, Hentgen V, Stojanovic KS, et al. How should we approach
19 classification of autoinflammatory diseases? *Nat Rev Rheumatol*
20 2013; 9: 624-629
21
22 60. Wekell P, Berg S, Karlsson A, et al. Towards an inclusive, congruent,
23 and precise definition of autoinflammatory diseases. *Frontiers in*
24 *Immunol.* 2017, Vol 8 Article 497.
25
26
27 61. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigm
28 and nomenclature. *J Med Genet* 2013; 50:349-359.
29
30 62. de Jesus A, Canna S W, Liu Y, Goldbach-Mansky R., Molecular
31 Mechanisms in Genetically Defined Autoinflammatory Diseases:
32 Disorders of Amplified Danger Signaling. *Annu Rev Immunol.* 2015 ;
33 33: 823–874.
34
35
36 63. Milner J D. PLAID: A syndrome of complex patterns of disease and
37 unique phenotypes. *J Clin Immunol.* 2015; 35: 527– 530.
38
39
40
41 64. Rodero MP, Yanick J, Crow J Y, Type I interferon–mediated
42 monogenic autoinflammation: The type I interferonopathies, a
43 conceptual overview *J Exp Med* 2016; 213: 2527–2538
44
45
46 65. Shimizu M, Tone Y, Toga A, et al. Colchicine-responsive chronic
47 recurrent multifocal osteomyelitis with MEFV mutations: a variant of
48 familialMediterranean fever? *Rheumatology*, 2010; 49:2221– 2223
49
50
51 66. Ben-Chetrit E, Ozdogan H. Can we make a diagnosis of
52 autoinflammaty diseases based upon clinical features only? *Clin Exp*
53 *Rheumatol* 2017, (35 Suppl) 108(6):16-18.
54
55
56
57
58
59
60

- 1
2
3 67. Prietsch, V., Mayatepek, E., Krastel, H., et al. Mevalonate kinase
4 deficiency: enlarging the clinical and biochemical spectrum. *Pediatrics*
5 111: 258-261, 2003
6
7 68. Hofmann S R, Kapplusch F, Girschick H J et al. Chronic Recurrent
8 Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and
9 Treatment. *Curr Osteoporos Rep.* 2017; 15(6): 542–554
10
11
12 69. de Koning H D, van Gijn M E, Stoffels M, Myeloid lineage–restricted
13 somatic mosaicism of *NLRP3* mutations in patients with variant
14 Schnitzler syndrome. *J Allergy Clin Immunol* 2015;135: 561-564.
15
16 70. Peckham D, Scambler T, Savic S, et al. The burgeoning field of
17 innate immune-mediated disease and autoinflammation. *J Pathol*
18 2017; 241: 123 –139.
19
20
21 71. Artis D, Spits H. The biology of innate lymphoid cells, *Nature* 2015;
22 517:293-301
23
24 72. Holzinger D, Fassl S K, de Jager W, et al, Single amino acid charge
25 switch defines clinically distinct proline-serine-threonine phosphatase-
26 interacting protein 1 (PSTPIP1)–associated inflammatory diseases *J*
27 *Allergy clin immunol* 2015;136:1337-1345
28
29 73. Karacan I, Uğurlu S, Tolun A, et al. Other autoinflammatory disease
30 genes in a FMF-prevalent population: A homozygous missense MVK
31 mutation and a novel heterozygous TNFRSF1A mutation in two
32 different Turkish families with clinical FMF. *Clin Exp Rheumatol* 2017,
33 35 Suppl 108(6):75-81
34
35 74. Brehm A, Liu Y, Sheikh A et al. Additive loss-of-function proteasome
36 subunit mutations in CANDLE/PRAAS patients promote type I IFN
37 production. *J clin Invest* 2015:125:4196 – 4211
38
39
40 75. Rigaud S, Fondanèche MC, Lambert N et al. XIAP deficiency in
41 humans causes an X-linked lymphoproliferative syndrome. *Nature.*
42 2006 ;444:110-4.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Glossary - Abbreviations

AGS - Aicardi-Goutières Syndrome

AIDs - Autoinflammatory diseases

AIMDs - Autoimmune diseases

ALPS - Autoimmune lymphoproliferative syndrome

APR - Acute phase reactant

CANDLE - Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome

CAPS - Cryopyrin-associated periodic fever syndrome

CARD - Caspase recruitment domain family member

CINCA- Chronic infantile neurologic, cutaneous and articular syndrome

CNO - Chronic non-bacterial osteomyelitis

CRMO -Chronic recurrent multifocal osteomyelitis

ADA2 - adenosine deaminase 2

DIRA - Deficiency of the interleukin 1 receptor antagonist

DITRA - Deficiency of the interleukin 36 receptor antagonist

FCAS - Familial cold autoinflammatory syndrome

FMF - Familial Mediterranean fever

HIDS - Hyper-IgD with periodic fever syndrome

HOIL -1 - Heme - oxidised IRP2 ubiquitin ligase 1

IBD - Inflammatory bowel disease

ISSAID - International society for systemic autoinflammatory diseases

JMP - Joint contractures, muscle atrophy, microcytic anemia and panniculitis-induced lipodystrophy.

LOGRUF - Late onset gammopathy with recurrent urticarial and fever

MEFV - Mediterranean fever

MK- Mevalonate kinase

1
2
3 **MKD** - Mevalonate kinase deficiency
4
5 **MVK** - Mevalonate kinase
6
7 **MWS** - Muckle-Wells syndrome;
8
9 **NALP 12**- NACHT, LRR and PYD domains-containing protein 1
10
11 **NGS** - New generation sequencing
12
13 **NLR** - NOD-like receptor
14
15 **NLRC4** - NOD-like receptor with CARD containing 4
16
17 **NLRP** - NOD-like receptor with LRR (Leucine rich repeat), and PYD domain;
18
19 **NOD** - Nucleotide-binding oligomerization domain;
20
21 **NOMID** - Neonatal onset multisystem inflammatory disease
22
23 **PAAND** - Pyrin-associated autoinflammation with neutrophilic dermatosis
24
25 **PAMI** - *PSTPIP1*-associated myeloid-related proteinemia inflammatory syndrome
26
27 **PAPA** - *PSTPIP1* arthritis, pyoderma gangrenosum, and acne
28
29 **PFAPA**: Periodic fever, aphthous stomatitis, pharyngitis and adenitis
30
31 **PLD** - *PLCG2* dysregulation
32
33 **PLAID** - *PLCG2*-associated antibody deficiency and immune dysregulation
34
35 **PLCG2** - Phospholipase C γ 2
36
37 **POMP** - proteasome maturation protein
38
39 **PRINTO** - Pediatric rheumatology international trials organization
40
41 **PRAAS** - Proteasome associated autoinflammatory syndrome
42
43 **PSMB 3-4,8-9** - Proteasome Subunit, β -type, 3,4,8,9
44
45 **PSTPIP1** - proline serine threonine phosphatase-interacting protein 1
46
47 **-SAPHO** - synovitis, acne, pustulosis, hyperostosis, and osteitis
48
49 **SDCM** - SH3BP2 deficiency with multilocular cystic disease of the mandibles.
50
51 **SH3BP2** - SH3 Domain Binding Protein2
52
53 **SAP** - SLAM - associated protein
54
55 **SLE** - systemic lupus erythematosus
56
57 **TNF** - Tumor necrosis factor
58
59
60

1
2
3 **TNFRSF1A** - Tumor necrosis factor receptor super family 1A

4 **TRAPS** - TNF-receptor-associated periodic syndrome

5
6 **XIAP** - X-linked Inhibitor of Apoptosis
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Table 1. Current name of the disorder (in bold) and additional names (normal characters) derived from the literature. The last column reports the proposed nomenclature for the AIDs as results of the consensus process.

Current name of the disorder and additional names	Proposed nomenclature
CAPS - Cryopyrin-associated periodic fever syndrome [20] CINCA - Chronic infantile neurological, cutaneous and articular syndrome [17], NOMID - Neonatal onset multisystem inflammatory disease	<i>NLRP3</i>-associated autoinflammatory disease (<i>NLRP3</i>-AID) Severe
MWS - Muckle-Wells syndrome [18]	Moderate
FCAS - Familial cold autoinflammatory syndrome [19]	Mild
<i>CARD14</i>-associated disease PRP - Familial Pityriasis rubrapilaris [30] CAMPS - <i>CARD14</i> -mediated pustular psoriasis [31]	<i>CARD14</i>-associated psoriasis
Cherubism [45] Familial Multilocular Cystic Disease of the Jaws [46] Cherubism--familial fibrous dysplasia of the jaws [47] CGCL - Central giant cell lesion [48]	<i>SH3BP2</i> deficiency with multiocular cystic disease of the mandibles (SDCM)
CRMO - Chronic recurrent multifocal osteomyelitis [29] Majeed syndrome [26], Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis [27] LIPIN2-associated disease [28]	Chronic non-bacterial osteomyelitis (CNO) - (when the gene is known it should be added) <i>LPIN2</i>-CNO
DIRA – Deficiency of the IL-1 receptor antagonist [24]	(No change)
DITRA - Deficiency of the IL-3 6receptor antagonist [25]	(No change)
FCAS2 – Familial cold autoinflammatory syndrome 2 [36] Guadeloupe fever, NALP12 periodic fever	<i>NLRP12</i>-associated autoinflammatory disease (<i>NLRP12</i>-AID)

Current name of the disorder and additional names	Proposed nomenclature
syndrome [36]	Pyrin-associated autoinflammatory disease (PAAD)
FMF - Familial Mediterranean fever (FMF)[7] Benign paroxysmal peritonitis [4] , Periodic disease [5], Armenian disease, Periodic disease "Maladie periodique" [6], Familial Mediterranean fever (FMF) [7], Recurrent polyserositis [8], Familial paroxysmal polyserositis [9]	(No change)
PAAND - Pyrin-associated autoinflammation with neutrophilic dermatosis [10]	(No change)
JMP Joint contractures, Muscle atrophy, Microcytic Anemia and Panniculitis Induced Lipodystrophy [38], Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome [37], Nakajo-Nishimura Syndrome (NNS) [39]	Proteasome-associated autoinflammatory syndrome (PRAAS) PSMB8-PRAAS, PSMB4/PSMB9-PRAAS, PSMB4/PSMB9-PRAAS, PSMA3/PSMB8-PRAAS
HIDS - Hyper IgD syndrome [15] Mevalonic aciduria (67) Mevalonate kinase disease (Deficiency) [13, 14] Dutch type periodic fever [16]	Mevalonate kinase deficiency (MKD) Mild Severe (Add porokeratosis or retinitis pigmentosa when present)
IL-10 Deficiency IBD - IL-10R-associated very early [32] Infantile colitis [33]	IL-10 deficiency-associated Inflammatory bowel disease
NOD2 CARD15-Associated disease Blau syndrome [21], Early onset sarcoidosis [22], Familial Crohn's disease [23]	NOD2-associated granulomatous disease (Optional: add Blau syndrome or IBD according to the main clinical features)
PAPA / Pyogenic Arthritis, Pyoderma gangrenosum, and Acne syndrome [35]	PSTPIP1-associated arthritis, pyoderma gangrenosum, and acne (PAPA)

Current name of the disorder and additional names	Proposed nomenclature
<p>PFAPA - Periodic fever, aphthous stomatitis, pharyngitis and adenitis Periodic fever, aphthous stomatitis, pharyngitis and adenitis or periodic fever aphthous pharyngitis and cervical adenopathy [41] Marshall's syndrome [42]</p>	<p>(No change)</p>
<p>Schnitzler syndrome [40] PUPAP - Periodic fever with urticaria and paraprotein</p>	<p>(No change)</p>
<p>TRAPS - TNF receptor-associated periodic fever syndrome[3] Familial Hibernian fever [11] Familial autosomal dominant periodic fever [12]</p>	<p>(No change)</p>

Table 2. Results from the Delphi questionnaires for consensus on nomenclature

Definition or Disease	Group of AIDs experts consensus (N=26)
Definition	
Autoinflammatory diseases are clinical disorders caused by defect(s) or dysregulation of the innate immune system, characterized by recurrent or continuous inflammation (elevated APR) and by the lack of a <i>primary</i> pathogenic role of the adaptive immune system (auto - reactive T-cells or autoantibody production).	87%
Final names proposed for the AIDs	
CARD14-associated psoriasis	91%
CNO: Chronic non-bacterial osteomyelitis	87%
DIRA: Deficiency of the IL-1 receptor antagonist	96%
DITRA: Deficiency of the IL-36 receptor antagonist	96%
IL-10 deficiency-associated inflammatory bowel diseases	83%
PAAD: Pyrin-associated autoinflammatory disease: FMF, PAAND	88%
MKD: Mevalonate kinase deficiency	87%
NLRP3-AID – NLRP3-associated autoinflammatory disease	88%
NLRP12-AID – NLRP12-associated autoinflammatory disease	88%
NOD2-associated granulomatous diseases	83%
PAPA: PSTPIP1-associated arthritis, pyoderma gangrenosum and acne	87%
PFAPA: Periodic fever, aphthous stomatitis, pharyngitis and adenitis	83%
PRAAS : Proteasome-associated autoinflammatory syndrome	84%
Schnitzler syndrome	87%
SDCM - SH3BP2 deficiency with multilocular cystic disease of the mandibles	94%
TRAPS - TNF receptor-associated periodic fever syndrome	83%

Table 3. Recommendations for naming AIDs

1. Try not to change wherever the name is appropriate.
2. Avoid names of persons or geographical spread of disease (eponyms)
3. Include the genetic basis (name of the gene) of the disease where it is known (prefer the name of the gene over the name of the encoded protein unless the name of the gene is not accurate or meaningless)
4. Include key clinical features where appropriate
5. Shorten the name as much as possible
6. Choose a name that is as clear as possible
7. In diseases where our knowledge about the pathogenesis is still limited, leave the previous name (PFAPA)
8. In diseases with different phenotypes but mutations in the same gene, use a general "roof" name with subtypes (PAAD, NOD2).
9. When the clinical features seemed to be "continuous" give a general name ("roof" name) and classify the various presentations according to their phenotypic severity (*NLRP3-AID, MKD*).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends to figure

Figure 1

The group of diseases associated with *MEFV* sequence alterations. The "roof" name is a general name whereas the subtypes are more specific and meaningful.

Confidential: For Review Only



The group of diseases associated with MEFV sequence alterations. The "roof" name is a general name whereas the subtypes are more specific and meaningful.

106x51mm (300 x 300 DPI)

Supplementary figure S1

Literature review for the definitions of Autoinflammatory diseases using the MESH search term: “autoinflammatory diseases” and subsequently all names reported in Table 1.




Table 1 Supplementary: Current name of the disorder and additional names derived from the literature. The last column reported the proposed nomenclature for the AIDs as results of the consensus process.

Current name of the disorder	Additional names	OMIM	Name of the gene	Name of the protein	Proposed nomenclature
CAPS Cryopyrin-associated periodic fever syndrome [20]		120100	<i>NLRP3/CIAS1</i>	Cryopyrin	Roof name: <i>NLRP3</i>-associated autoinflammatory disease (<i>NLRP3</i>-AID)
	Chronic infantile neurological, cutaneous and articular syndrome (CINCA)[17] Neonatal onset multisystem inflammatory disease (NOMID)	607115			Severe
	Muckle-Wells syndrome (MWS) [18]	191900			Moderate
	Familial cold autoinflammatory syndrome (FCAS) [19]				Mild
<i>CARD14</i>-associated disease		<i>CARD14</i>	<i>CARD14</i>		<i>CARD14</i>-associated psoriasis
	Familial Pityriasis rubrapilaris (PRP) [30]				

Current name of the disorder	Additional names	OMIM	Name of the gene	Name of the protein	Proposed nomenclature
	CAMPS - CARD14-mediated pustular psoriasis [31]				
Cherubism [45]		266270	<i>SH3BP2</i>	SH3BP2	SH3BP2 deficiency with multi locular cystic disease of the mandibles (SDCM)
	Familial Multilocular Cystic Disease of the Jaws [46]				
	Cherubism--familial fibrous dysplasia of the jaws [47]				
	Central giant cell lesion (CGCL) [48]				
CRMO Chronic recurrent multifocal osteomyelitis [29]					Chronic non-bacterial osteomyelitis (CNO) (when the gene is known it should be added)
	Majeed syndrome [26]	609628	<i>LPIN2</i>	LIPIN 2	
	Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis [27]				
	<i>LIPIN2</i> -associated disease [28]				LIPIN2-CNO
DIRA Deficiency of the IL-1		612852	<i>IL1RN</i>	IL-1Ra	(No change)

Current name of the disorder	Additional names	OMIM	Name of the gene	Name of the protein	Proposed nomenclature
receptor antagonist [24]					
DITRA Deficiency of the IL-36R antagonist [25]		614204	<i>IL36RN</i>	IL-36Ra	(No change)
FCAS 2 Familial cold autoinflammatory syndrome 2 [36]		611762	<i>NLRP12</i>	NLRP12	<i>NLRP12</i>-associated autoinflammatory disease (<i>NLRP12</i>-AID)
	Guadeloupe fever				
	NALP12 periodic fever syndrome [36]				
					Roof name: Pyrin-associated autoinflammatory disease (PAAD)
FMF Familial Mediterranean fever[7]		134610 249100	<i>MEFV</i>	Pyrin	(No change)
	Benign paroxysmal peritonitis [4]				
	Periodic disease [5]				
	Armenian disease				
	Periodic disease "Maladie periodique" [6]				
	Familial Mediterranean fever				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Current name of the disorder	Additional names	OMIM	Name of the gene	Name of the protein	Proposed nomenclature
	(FMF) [7]				
	Recurrent polyserositis [8]				
	Familial paroxysmal polyserositis [9]				
PAAND Pyrin-associated autoinflammation with neutrophilic dermatosis [10]					(No change)
					Roof name: Mevalonate kinase deficiency (MKD)
HIDS Hyper IgD syndrome [15]	Mevalonate kinase disease (Deficiency) [13, 14]	260920	<i>MVK</i>	Mevalonate kinase	Mild
	Dutch type periodic fever [16]				
Mevalonic aciduria (67)					Severe
					(Add porokeratosis or retinitis pigmentosa when present)
					Roof name: Proteasome-associated

Current name of the disorder	Additional names	OMIM	Name of the gene	Name of the protein	Proposed nomenclature
					autoinflammatory syndrome (PRAAS)
JMP Joint contractures, Muscle atrophy, Microcytic Anemia and Panniculitis Induced Lipodystrophy[38]		256040	<i>PSMB8</i>	Proteasome subunits and others	<i>PSMB8</i> -PRAAS <i>PSMB4/PSMB9</i> -PRAAS <i>PSMA3/PSMB8</i> -PRAAS
	Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome [37]				
	Nakajo-Nishimura Syndrome (NNS) [39]				
IL-10 Deficiency		612567 613148	<i>IL10RA</i> or <i>IL10RB</i>		IL-10 deficiency-associated Inflammatory bowel disease
	IL-10R-associated very early IBD [32]				
	Infantile colitis [33]				
<i>NOD2 (CARD15)</i>-associated disease		186580	<i>NOD2/CARD15</i>	NOD2	Roof name: <i>NOD2</i>-associated granulomatous disease (Optional: add Blau syndrome or IBD according to the main clinical features)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Current name of the disorder	Additional names	OMIM	Name of the gene	Name of the protein	Proposed nomenclature
	Blau syndrome [21]				
	Early onset sarcoidosis [22].				
	Familial Crohn's disease [23]				
PAPA PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne) [35]		604416	<i>PSTPIP1</i>	CD2BP1 (CD2-binding protein1)	<i>PSTPIP1</i>-associated arthritis, pyoderma gangrenosum, and acne (PAPA)
PFAPA					(No change)
Periodic fever, aphthous stomatitis, pharyngitis and adenitis	Periodic fever, aphthous stomatitis, pharyngitis and adenitis or periodic fever aphthous pharyngitis and cervical adenopathy [41]				
	Marshall's syndrome [42]				
Schnitzler syndrome [40]					(No change)
	Periodic fever with urticaria and paraprotein (PUPAP)				
TRAPS - TNF receptor-associated periodic fever		142680	<i>TNFRSF1A</i>	TNFR1	(No change)

Current name of the disorder	Additional names	OMIM	Name of the gene	Name of the protein	Proposed nomenclature
syndrome[3]					
	Familial Hibernian fever [11]				
	Familial autosomal dominant periodic fever [12]				

Consensus proposal for Taxonomy and Definition of the Autoinflammatory Diseases (AIDs) - A Delphi Study

Eldad Ben-Chetrit¹, Marco Gattorno², Ahmet Gul³, Daniel L Kastner⁴, Helen J Lachmann⁵, Isabelle Touitou⁶ and Nicolino Ruperto⁷ for the Paediatric Rheumatology International Trials Organisation (PRINTO) and on behalf of the AIDs Delphi study participants*

Rheumatology Unit, Hadassah Hebrew University Medical Center¹, Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy², Department of Internal Medicine, Division of Rheumatology, Istanbul University Faculty of Medicine, Istanbul, Turkey³, Inflammatory Disease Section, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, US National Institutes of Health, Bethesda, Maryland, USA⁴, Centre for Amyloidosis & Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London Medical School, London, UK⁵, CEREMAIA, CHU Montpellier, Université de Montpellier, INSERM U1183⁶, Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia – PRINTO, Genoa, Italy⁷

*List of additional participants to the Delphi study

Ivona Aksentijevich, Bethesda, USA

Jordi Anton, Barcelona, Spain

Juan I Arostegui, Barcelona, Spain

Karyl S. Barron, Bethesda, USA

Luca Cantarini, Siena, Italy

Fatma Dedeoglu, Boston, MA, USA

Erkan Demirkaya, London, ON, Canada

Dirk Foell, Muenster, Germany

Joost Frenkel, Utrecht, Netherlands

Philip J. Hashkes, Jerusalem, Israel

Veronique Hentgen, Paris, France

Michael Hofer, Lausanne, Switzerland

Tilman Kallinich, Berlin, Germany

Isabelle Koné-Paut, Paris, France

Jasmin B. Kuemmerle-Deschner, Tuebingen, Germany

Ronald Laxer, Toronto, ON, Canada

Avi Livneh, Ramat Gan, Israel

Alberto Martini, Genoa, Italy

Laura Obici, Pavia, Italy

Formatted: Italian (Italy)

Formatted: English (U.S.)

1
2
3
4
5
6 Seza Ozen, Ankara, Turkey
7 Dorota Rowczenio, London, United Kingdom
8 Ricardo Russo, Buenos Aires, Argentina
9 Yael Shinar, Tel Hashomer, Israel
10 Natasa Toplak, Ljubljana, Slovenia
11 Yosef Uziel, Kfar Saba, Israel
12 Marielle van Gijn, Utrecht, The Netherlands
13
14

Formatted: Italian (Italy)

15
16 Key words: Taxonomy, Autoinflammatory diseases, immune system
17
18

19 Short running title: Taxonomy and definition of AIDs
20
21
22
23
24

25 Corresponding author:
26

27 Eldad Ben-Chetrit, MD
28

29 Professor of Medicine (Rheumatology)
30

31 Rheumatology Unit
32

33 Hadassah-Hebrew University Medical Center
34

35 Jerusalem, Israel
36

37 POB: 12000
38

39 Tel: ++ 972-2-6777111
40

41 Fax: ++972-2-6777394
42

43 E-mail: eldad@hadassah.org.il
44
45
46
47
48
49
50
51
52
53
54

Abstract

Background: Autoinflammatory diseases (AIDs) are a relatively new family of disorders defined about 19 years ago. Some of them are hereditary and some are not. The names given to these diseases do not follow any systematic guidelines and sometimes the same disorder carries several names.

Aims: The aim of this study is to refine the definition of the autoinflammatory diseases and to provide some conventions for their naming. We have focused our attention mainly on monogenetic AIDs.

Methods: Delphi technique which enables consensus among a group of experts through Internet and mail communication and questionnaires - was employed. After achieving 100% consensus among 6 members of a steering committee, the questionnaire containing the AID definitions and the agreed-upon conventions, were sent to 26 physicians and researchers working in the field of AIDs in order to gain broader support for the committee's proposals.

Results: The committee proposed the following definition for AIDs "Autoinflammatory diseases are clinical disorders caused by defect(s) or dysregulation of the innate immune system, characterized by recurrent or continuous inflammation (elevated acute phase reactants-APR) and the lack of a *primary* pathogenic role for the adaptive immune system (autoreactive T-cells or autoantibody production)". Several rules were defined for guiding the naming of these diseases among which are: abandoning eponyms and preferring the name of the gene over its encoded protein.

Conclusions: The new definition for AIDs allows inclusion of clinical disorders mainly associated with defects in the innate immune system. The new conventions propose names with clinical meaning and in some cases even clues for treatment.

1
2
3
4
5
6 Taxonomy is the science of naming. It is relevant to all fields of biology in which we
7 name plants, animals, objects and diseases. In medicine, naming of diseases or
8 syndromes has a special importance since it can give some clue about the nature of
9 the clinical condition, its clinical features, pathogenesis and sometimes even an
10 approach to treatment. Naming is also important for accurate and effective
11 communication among different health disciplines. However, medical disorders have
12 not been named in a standard way [1]. Physicians, who treat patients with a
13 particular disorder or face a new clinical condition, are often the first to propose a
14 name for the disease. Expert working groups may later revise the names to improve
15 their usefulness.
16
17
18

19
20 Names of medical disorders are often derived from one or a combination of the
21 following sources: genetic basis or biochemical defect; geographic spread; or by
22 eponyms. The main drawback of many names is the lack of a clinical meaning that
23 could help the novice to understand the origin of the disease or recognize its clinical
24 characteristics .
25
26

27 The autoinflammatory diseases (AIDs) are a group of medical disorders, derived from
28 defects or dysregulation of the innate immune system [2]. This family of diseases
29 was established in 1999 following the identification of the genes underlying two
30 recurrent fever syndromes: familial Mediterranean fever (FMF) [3,4] and TNF-
31 receptor-associated periodic syndrome (TRAPS) [5]. Over the last 18 years, more
32 and more diseases have been classified amongst this group of disorders, some of
33 which may not fit well with the classical definition of the AIDs. Moreover, many of
34 them were given names with no systematic guidelines or rules. In some cases, the
35 same disease carries several names (Table 1) [6-50]. This has led to a chaotic
36 situation in naming these clinical disorders and has called for a better standardization
37 of this field. This need is accentuated by recent progress in next generation
38 sequencing techniques (NGS), which have led to an increasing capability to identify
39 new genes and new syndromes, expanding the spectrum of AIDs.
40
41
42
43

44 Indeed, following the International Society for Systemic Autoinflammatory Diseases
45 (ISSAID) meeting in Lausanne, in 2013, a mandate was given to one of us (E B-C) to
46 undertake a preliminary consensus based exercise for the following aims: a. to refine
47 the definition of the "autoinflammatory diseases". b. to provide some rules and new
48 proposals for naming this current group of clinical conditions and those that will be
49 identified in the future.
50
51
52
53
54

Methods

In order to find the different definitions proposed for AIDs over the years, we searched the MEDLINE/PubMed Central® (PMC) from 1998 to January 2016, using the MESH search term: “autoinflammatory diseases” (supplementary Figure S1). In order to find the names used for each AID, we took one of their current names as depicted in Table 1 and searched for papers where they were first reported. Then, we searched for reviews on these items to find additional synonymous names. ~~Table 1 is based on a list of AIDs published by one of the authors (IT) [51], properly integrated and updated during the consensus process and finally approved by all the steering committee members. Table 1 is based on a list of AIDs published by one of the authors (IT) [51] and gained consensus by all the steering committee members.~~ It focused - mainly - on monogenic disorders.

For choosing the best definition for AIDs and the most appropriate name for each AID, we have used the Delphi technique, which enables consensus among a group of experts through mail communication [52]. The Delphi method is essentially a series of questionnaires involving several steps, each of which is based on the results of the previous step. The process stops when consensus of at least 80% of the participants on each item is reached. [53]

An *ad hoc* steering committee of 6 clinicians and researchers from 6 different countries who are working in the field of autoinflammation was established.

The first Delphi questionnaire was built through sending broad and open-ended questions in order to elicit different opinions from the panelists about the current definitions and names of AIDs.

Once received, the replies from the panelists were analyzed to generate a series of statements that were employed as the basis for follow up questionnaires that were sent back to the individual participants. In each subsequent questionnaire, the panelists were also provided with the overall results (responses) of the previous questionnaire from all the members. After achieving 100% consensus among the steering committee members, the questionnaire containing the AID definitions and the agreed-upon names of AIDs were sent to 26 physicians and researchers working in the field of AIDs around the world. They were identified in the Paediatric Rheumatology International Trials Organization (PRINTO) mailing list through their high active participation in the Eurofever registry [54, 55]. The aim of this step was to gain broader support for the committee's proposals and to consider changes once a name was rejected by or was not acceptable to more than 80% of the participants of

Formatted: English (U.S.)

Formatted: Font: (Default) +Body CS (Arial),
Font color: Auto, English (U.S.)

Formatted: Font color: Auto

Formatted: Font: English (U.S.)

1
2
3
4
5
6 the large group of AIDs experts. Delphi survey implementation was conducted by
7 PRINTO [56].
8
9

10 **Results**

11 **AIDs proposed definition**

12
13 The literature review disclosed 536 papers of which only 7 specifically dealt with the
14 definitions of AIDs [5, 57- 62] (supplementary Figure S1). The first definition for AIDs
15 was proposed by the NIH group in 1999 [5]. This definition was as follows: "The
16 autoinflammatory syndromes are systemic disorders characterized by apparently
17 unprovoked inflammation in the absence of high-titer autoantibodies or antigen-
18 specific T lymphocytes". This definition was based mainly upon the two diseases
19 whose related genes had then been identified: FMF and TRAPS [3- 5]. Since in both
20 diseases the flares appeared mostly spontaneous, the definition included the word
21 "unprovoked". The definition stresses the lack of involvement of the adaptive immune
22 system in these disorders, since no autoantibodies or autoreactive T-cells were
23 involved.
24
25

26
27
28
29 Seven years later McGonagle and McDermott suggested another definition: "AIDs
30 are characterized by self-directed inflammation, whereby local factors at sites
31 predisposed to disease lead to activation of innate immune cells, including
32 macrophages and neutrophils, with resultant target tissue damage. For example,
33 disturbed homeostasis of canonical cytokine cascades (as in the periodic fevers),
34 aberrant bacterial sensing (as in Crohn's disease), and tissue micro-damage
35 predispose one to site-specific inflammation that is independent of adaptive immune
36 responses" [57]. The authors proposed that immunological diseases ought to be
37 conceived as a continuum with "pure monogenic autoinflammatory diseases" at one
38 end and "pure monogenic autoimmune diseases" at the other. This definition is
39 relatively complex, but explicitly invokes innate immunity and widens the spectrum of
40 AIDs.
41
42
43
44
45

46 Later, several other definition or refinement were proposed [58-61]. In a recent study,
47 de Jesus et al. provide an outstanding classification of AIDs strictly based on their
48 pathophysiology [62]. However, the authors do not propose a new definition for the
49 AIDs.
50

51 Given the proliferation of AID definitions, with sometimes conflicting concepts, the
52 steering committee agreed to adopt the first and original definition with minor
53
54

1
2
3
4
5
6 modifications: "Autoinflammatory diseases are clinical disorders caused by defect(s)
7 or dysregulation of the innate immune system, characterized by recurrent or
8 continuous inflammation (elevated - APR) and the lack of a *primary* pathogenic role
9 for the adaptive immune system (autoreactive T-cells or autoantibody production)."

11 This definition emphasizes the essential fact that the disorders are caused by defects
12 in the innate immune system and are continuous or recurrent. The word
13 "unprovoked" has been deleted since in many cases there is a trigger for the acute
14 flares.
15
16

17 The steering committee is aware that diseases such as PLCG2-associated antibody
18 deficiency and immune dysregulation (PLAID) or Heme - oxidised IRP2 ubiquitin
19 ligase1 (HOIL-1) deficiency, traditionally included among the AIDs, will not be part of
20 this group, because they may contain components of the adaptive immune system
21 such as autoantibodies [63]. The "Interferonopathies" include some disorders also
22 manifesting autoantibodies. However, the consensus seemed to be that for disorders
23 like Aicardi-Goutières Syndrome (AGS) in which nucleic acid sensing is primarily
24 intracellular, autoantibodies usually play a minor role in disease pathogenesis, and
25 thus the autoinflammatory designation may still be appropriate. In their recent review
26 Rodero and Crow propose that "type I interferonopathies can reasonably be
27 considered as autoinflammatory in origin, with 'spill-over' into autoimmunity in some
28 cases" [64]. The group of "typical" **autoimmune diseases** includes disorders
29 affecting primarily or only the adaptive system such as systemic lupus erythematosus
30 (SLE), Hashimoto thyroiditis, DNase deficiencies and autoimmune
31 lymphoproliferative syndrome (ALPS).
32
33
34
35
36
37

38 **AIDs proposed nomenclature**

39
40 The current names for AIDs bring several problems and issues, which called for a
41 new approach and nomenclature modification; many AIDs possess more than a
42 single name (FMF - 7 different names, TRAPS - 3, etc) (Table 1 [and Supplementary](#)
43 [Table S1](#)); different clinical presentations are associated with similar sequence
44 alterations in the same gene eg. Muckle-Wells syndrome(MWS), familial cold
45 autoinflammatory syndrome (FCAS) and Neonatal onset multisystem inflammatory
46 disease (NOMID) are associated with *NLRP3* gene whereas FMF and pyrin-
47 associated autoinflammation with neutrophilic dermatosis (PAAND) are associated
48 with *MEFV* gene. In addition discussion arose about several topics briefly
49 summarized herein: In naming AIDs should we use the name of the gene or that of
50
51
52
53
54

1
2
3
4
5
6 the encoded protein (*MEFV* or pyrin)? Should we include typical clinical features or
7 just genetic attributes? Should historical names be retained?
8

9 Following more than 6 cycles of Delphi questionnaires and oral discussions among
10 the 6 members of the steering committee with further involvement of the 26 AIDs
11 experts around the world - a consensus of at least 80% was reached for the
12 nomenclature of the diseases shown in Tables 1 and 2.
13
14

15 **General conventions (Table 3)**

16
17 The proposed names for AIDs have been established according to the rules and
18 suggestions outlined in Table 3.
19

20 In many diseases the course of the disease is episodic with frequent attacks and
21 attack-free intervals. When the frequency of the attacks is relatively regular (as is the
22 case with Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) and
23 sometimes with mevalonate kinase deficiency (MKD) we preferred the term
24 "periodic". When the attacks do not have a regular pattern, we suggested the word
25 "recurrent".
26
27
28

29 In the past, both terms, "periodic" and "recurrent", have been used interchangeably
30 but now the term "periodic" remained in the names of 3 conditions only; Cryopyrin-
31 associated periodic fever syndrome (CAPS), TRAPS and PFAPA. In TRAPS, we
32 decided to keep the original name "periodic", although its flares are recurrent rather
33 than periodic. In CAPS, we propose a new name (NLRP3-AID) which does not
34 contain the word "periodic since the attacks are not periodic". Thus, we strongly
35 suggest using the more appropriate terms in naming disorders in the future.
36
37
38

39 As a general rule, we tried to use names containing etio-pathological (genetic)
40 features of the disease and where appropriate or possible, to add a significant clinical
41 characteristic of the syndrome. Thus, we left the name TRAPS without change, since
42 it consists of its genetic etiology (mutations in *TNFRSF1A* gene) and characteristic
43 clinical features [periodic (recurrent) fever]. On the other hand, the name hyper IgD
44 syndrome (HIDS) was abandoned since it is an absolutely inaccurate name: serum
45 IgD is not always elevated in these patients while it may be elevated in other AIDs.
46 Therefore, this name was replaced by MKD based upon our knowledge of the gene
47 involved, mevalonate kinase (*MVK*). In this way, a physician or researcher who
48 approaches these names for the first time may have immediately a basic
49 understanding of the disorder and sometimes even a clue to the potential treatment.
50
51
52
53
54

1
2
3
4
5
6 In cases where the choice was between using the name of the gene associated with
7 the disease or the protein encoded by the gene, we preferred the name of the gene
8 over that of the protein unless the former was meaningless. A typical example is the
9 choice of *NLRP3* gene over cryopyrin despite the tendency of some clinicians to stay
10 with the former term CAPS. Fortunately, in many cases the name of the gene and the
11 encoded protein are the same (MK, NOD2) making the choice easier. However, this
12 was not the case with the *MEFV* gene and pyrin where the name of the protein was
13 chosen, as will be discussed later.
14
15

16
17 In our proposals for new taxonomy of AIDs, we tried to avoid the use of names of
18 persons (such as Nakajo Nishimura syndrome) or geographical distribution of the
19 disease (such as Guadeloupe fever) or names with unusual meaning (such as
20 "Cherubism").
21
22

23 **Specific names (Table 1 and Supplementary Table S1)**

24
25 In the case of CAPS – which encompasses three clinical entities (FCAS, MWS,
26 NOMID/CINCA), the committee has proposed using a single name; *NLRP3*-
27 associated autoinflammatory disease (*NLRP3*-AID). Since the various disorders
28 reflect different levels of phenotypic severity of the same disease, it was suggested to
29 add the adjectives: mild, moderate, and severe phenotypes, instead of using the
30 historical names FCAS, MWS and CINCA/NOMID, respectively.
31
32

33
34 In familial cold autoinflammatory syndrome 2 (FCAS2) (Guadeloupe fever), different
35 families present with different phenotypes [36]. Since the gene associated with the
36 disease (*NLRP12*) is known, the committee decided to name this syndrome *NLRP12*-
37 associated autoinflammatory disease (*NLRP12*-AID).
38
39

40 In the case of *MEFV*-associated diseases, the question raised was as follows: should
41 we use the old name FMF or "atypical FMF" for all syndromes associated with
42 mutations in the *MEFV* gene even if they have totally different clinical
43 manifestations? Alternatively, should we find a different way to classify these
44 disorders? The committee chose to use a general name (as a "roof") "pyrin-
45 associated autoinflammatory diseases" (PAAD) which includes all diseases
46 associated with pyrin defects or *MEFV* mutations. Under this general term, there are
47 subtypes of disorders with different names, according to their clinical presentation or
48 genetic features, such as: PAAND, FMF, etc. [65] (Figure 1). Although it is preferred
49 using the name of the gene over the name of the encoded protein, in the case of
50 FMF, the protein pyrin was chosen rather than the *MEFV* gene. One of the reasons
51
52
53
54

1
2
3
4
5
6 was that the name *MEFV*, which was coined to denote its association with familial
7 **Mediterranean fever**, is no longer accurate, since it may lead to totally different AIDs,
8 such as PAAND and CRMO-like disorder. In addition, we did not change the name of
9 familial Mediterranean fever (FMF), although sometimes it is neither familial nor
10 restricted to the Mediterranean basin and in rare cases, it may even be without a
11 documented fever. Most members of the steering committee thought that FMF is a
12 well-known and defined entity and that changing the name would cause discomfort
13 and confusion among the AID clinical community. The name FMF remained under
14 the "roof" of "pyrin-associated autoinflammatory diseases" (PAAD) as a clinical entity
15 which is restricted mainly to Middle Eastern patients or to patients elsewhere, whose
16 disease is associated with exon 10 mutations [66].
17
18
19
20

21 Regarding Mevalonate kinase disorders the committee suggested leaving MKD as a
22 general name with the option of adding "mild" for those with hyper IgD syndrome and
23 "severe" for those with mevalonic aciduria (67). In rare cases, where the patient with
24 MKD has also retinitis pigmentosa or porokeratosis, it is suggested to mention these
25 manifestations in addition to MKD (Table 1, and Supplementary Table S1).
26
27

28 The name *NOD2*-associated granulomatous disease was chosen by the committee
29 for the three phenotypes: Blau syndrome, familial sarcoidosis and familial Crohn's
30 disease. Since all these syndromes are characterized by granulomas, this feature
31 was included in the name. Nevertheless, an option was offered to add IBD in cases
32 where the intestines are the main site of involvement eg. *NOD2*-associated
33 granulomatous IBD (formerly called familial Crohn's disease).
34
35
36

37 The name for CRMO was replaced by the name chronic non-bacterial osteomyelitis
38 CNO. The reason for that was the presence of many cases where the disease was
39 neither recurrent nor multifocal. Furthermore, the new name emphasizes the main
40 feature of the disease, non-bacterial osteomyelitis. Since this clinical entity may be
41 associated with mutations in various genes, it is optional to add the name of the gene
42 when it is known. For example in case the gene involved is *LPIN2* it can be marked
43 as *LPIN2*-CNO (previously known as Majeed's syndrome). In adults, patients with
44 sporadic CNO are usually diagnosed with SAPHO, a symptom complex of Synovitis,
45 Acne, Pustulosis, Hyperostosis, and Osteitis [68].
46
47
48

49 Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature
50 syndrome (CANDLE syndrome) gained a new name: *PSMB8*-PRAAS - where
51 *PSMB8* stands for Proteasome Subunit Beta 8 and PRAAS for PRoteasome-
52 Associated Autoinflammatory Syndrome. This name replaces also the eponym
53
54

1
2
3
4
5
6 Nakajo Nishimura syndrome, and JMP which stands for Joint contractures, Muscle
7 atrophy, microcytic anemia and Panniculitis-induced lipodystrophy. The name
8 *PSMB8*-PRAAS consists of the genetic etio-pathology of the disorder but does not
9 include any clinical feature of the disease.
10

11
12 *CARD14*-associated disease is usually characterized by psoriasis with or without
13 pustulosis. Therefore, the name was refined to be *CARD14*-associated psoriasis.
14

15 Since the 3 variants of IL-10 deficiency are always associated with inflammatory
16 bowel disease, the committee proposed a single name as IL-10 deficiency-
17 associated IBD.
18

19
20 The names; deficiency of the interleukin 1 receptor antagonist (DIRA), deficiency of
21 the interleukin 36 receptor antagonist (DITRA), pyogenic arthritis, pyoderma
22 gangrenosum, and acne (PAPA) and PFAPA remained unchanged since they
23 already conform to our naming conventions. However, the letter P in the abbreviation
24 "PAPA" now stands for the name of the gene *PSTPIP1* rather than "Pyogenic" and,
25 therefore, the new name is "*PSTPIP1*-associated arthritis, pyoderma gangrenosum
26 and acne" (PAPA).
27
28

29
30 The name "Cherubism" was derived from the Biblical "cherub" (plural cherubim) who
31 has four faces of different species and several pairs of wings,. For most physicians
32 this name does not mean much and therefore, the committee proposed the name
33 *SH3BP2* deficiency with multilocular cystic disease of the mandibles (SDCM). This
34 name gives the etio-pathologic basis of the syndrome with the main clinical feature of
35 fibrous dysplasia of the mandibles.
36
37

38 Finally, the name "Schnitzler syndrome" also remained as an historical one, since its
39 pathogenesis is still obscure and its relationship with *NLRP3* mutations has not been
40 established [69]. A proposal to convert the name of the syndrome to a clinical
41 description: "late onset gammopathy with recurrent urticaria and fever" (LOGRUF)
42 did not gain support from most of the committee members.
43
44

45 **Discussion**

46
47 The definition of autoinflammatory diseases has changed over the years in order to
48 accommodate the new diseases discovered since 1999 – the year the term was first
49 proposed [2, 5, 57-61]. Widening the scope and spectrum of definition of AIDs
50 resulted in the inclusion of disorders with additional defects in the adaptive immune
51 system such as PLAID or HOIL-1 deficiency. Most defects in the immune system
52
53
54

1
2
3
4
5
6 may affect primarily either the innate or the adaptive arm. However, it is becoming
7 increasingly obvious that the innate immune system almost always has an effect on
8 the adaptive system. This leads to the situation that there are disorders that do not fit
9 neatly into the "pure" autoinflammatory or autoimmune categories, and reside
10 actually in a "grey zone" between these two groups. In order to include these
11 disorders with the typical AIDs under the same "rafter", Peckham et al. offered the
12 term "Auto-inflammatory-immune diseases" [70]. We believe that this new name may
13 lead to confusion since all the disorders caused or related to defects in the immune
14 system can be classified under this wide term with no clear categorization. The
15 interferonopathies are clinical disorders caused by defects in the innate response,
16 leading to inflammation after DNA sensing. The activation of cells of the adaptive
17 immunity is a secondary effect of this condition and seems to play a minor role in
18 their pathogenesis. Therefore, they may create the bridge which fits the concept that
19 the autoinflammatory diseases, and the autoimmune diseases are actually in the
20 same spectrum of immune disorders. This continuum model is further supported by
21 the recent discovery of the innate lymphoid cells (ILCs). These cells are defined by
22 differential expression of cell-surface markers and are activated by neuropeptides,
23 cytokines and other alarmins [71]. Their specialized distribution in lymphoid and non-
24 lymphoid tissues, coupled with their functional heterogeneity, has provoked a
25 fundamental reassessment of how they integrate innate and adaptive immune
26 responses.

27
28
29
30
31
32
33
34 As already mentioned - many of the current names of AIDs were not appropriate,
35 inaccurate or lack any clinical meaning. Therefore, an attempt to establish new
36 conventions for naming them was really needed.

37
38
39 The conventions (Table 3), and the ensuing proposals (Table 1, and Supplementary
40 Table S1), call for using the name of the gene associated with the disease when it is
41 known rather than the encoded protein. In these cases, demonstration of functional
42 significance of the identified sequence alteration is mandatory. The main advantage
43 of using the name of the gene is that such a name gives the physician a clue about
44 the pathogenesis of the disease and sometimes even about a potential treatment.
45 Moreover, it may allow definite diagnosis using genetic testing. However, it should be
46 borne in mind that including the gene in the name of the disease may pose a problem
47 in cases where the clinical features of the patient are compatible with a certain
48 diagnosis while no expected sequence alteration is found. Thus, the main drawback
49 of using the name of the gene is that **definite** diagnosis can be made only by genetic
50 testing.

1
2
3
4
5
6 In cases where the clinical features and the genetic testing results are in accord, the
7 name is appropriate and the diagnosis is correct and definite. When there is a clearly
8 pathogenic mutation but the clinical features are completely incompatible with the
9 expected diagnosis, one should consider a different disease with a different name.
10 This situation is illustrated by the case of the *MEFV* mutation S242R, which causes
11 neutrophilic dermatosis. The name of this disease is not "FMF" or "atypical FMF"
12 despite the fact that there are *MEFV* mutations - but "pyrin-associated
13 autoinflammation with neutrophilic dermatosis (PAAND)". Similar approach may be
14 applied in the case of *PSTPIP1* with the new mutation and different clinical
15 presentation [72]. We suggest here a "roof" name : *PSTPIP1*-associated
16 autoinflammatory diseases with two subtypes: PAPA and PAMI (*PSTPIP1*-
17 associated myeloid-related proteinemia inflammatory syndrome). However, we
18 cannot add this approach to Table 1 since it was not discussed in the Delphi
19 questionnaires among the large group of participants
20
21
22
23
24

25 When the clinical features are typical for a certain disease (for example FMF) and
26 yet no genetic support for this diagnosis is found, one can denote this medical
27 condition as an FMF-like disease. However, a better choice would be to leave the
28 case as an undefined AID until mutations in other genes are found or additional
29 explanations for the disease are given. The reason is that clinical features typical for
30 one AID may be associated with mutations in different genes. For example, in
31 arecent report, Karacan et al. described two Turkish families in whom 4 patients
32 presented with typical clinical features of FMF [73]. Genetic analysis performed in
33 these patients failed to show *MEFV* mutations. However, total exon sequencing
34 revealed that two patients were homozygous for mutations in *MVK* and the two other
35 patients carried mutations in the *TNFRSF1A* gene. These cases illustrate the
36 difficulties in making a diagnosis of AID based upon clinical features only and justify
37 the proposal to use the gene in naming AIDs wherever it is known.
38
39
40
41
42

43 The way we proposed naming CAPS and FCAS 2 namely NLRP3-associated
44 autoinflammatory disease (NLRP3-AID) and *NLRP12*-AID respectively may pave the
45 way for naming future disorders to be discovered or identified among the other
46 members of the large family of NOD-like receptors (NLRs).. Similarly, *PSMB8*-
47 PRAAS, the name which was proposed to replace CANDLE syndrome, JMP and
48 NNS, may also serve as an example for naming additional proteasome associated
49 diseases to be discovered, just by changing their number. In fact, Brehm et al.
50 recently described several cases that carry mutations in *PSMA3* (encodes $\alpha 7$),
51
52
53
54

1
2
3
4
5
6 *PSMB4* (encodes $\beta 7$), *PSMB9* (encodes $\beta 1i$), and proteasome maturation protein
7 (*POMP*) [74].
8

9 Unfortunately, the current study did not include many other monogenic AIDs such as
10 those associated with *ADA2*, *NLRC4*, *NLRP1* genes or X-linked inhibitor of apoptosis
11 (*XIAP*) deficiency and (SLAM)-associated protein (*SAP*) deficiency (75). The reason
12 is that we limited ourselves mainly to the basic list reported by Toitout et al.(51).
13 However, we hope that the conventions we propose herein may help modifying
14 names of additional diseases - old and new – when, they do not follow the rules
15 suggested.
16
17
18

19 For this project we used the Delphi technique which allowed discussion via an *ad hoc*
20 web-based system developed by the PRINTO staff under the supervision of NR who
21 has an extensive expertise in consensus formation methodologies. The PRINTO
22 system allowed remote interaction between the participants who had the possibility to
23 share written comments with the other participants in a transparent and traceable
24 way. A limitation of the current work was that for lack of funding we could not conduct
25 a formal nominal group technique (NGT) which is a guided face-to-face discussion
26 and interaction, among small groups of experts. However, the additional discussion
27 of the *ad hoc* steering committee consensus proposal by another group of 26
28 worldwide experts in the field of AIDs further strengthens these proposals.
29
30
31
32

33 In conclusion, the currently proposed rules for nomenclatures of AIDs are expected
34 to allow a better organization of these groups of immune diseases. However,
35 taxonomy is a dynamic process and some of the proposed names may be changed
36 in the future as we gain a better knowledge about their pathogenesis. The proposed
37 taxonomy may gain a broader consensus following an effective communication with
38 other societies such as the International Union of Immunological Societies Expert
39 Committee (IUIS).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Acknowledgements

We thank the staff from the PRINTO office (Eugenia Mosci, Luca Villa, and Roberto Cavanna).

Contributorship Statement

All authors (EBC, MG, AG, DLK, HJL, IT, NR) contributed equally to the planning and conduct of the study. Their placement in the authors' list is dictated by the alphabetic order of their family names.

The first version of the present manuscript was written by EBC, MG and NR, and then revised critically by all the remaining co-authors (AG, DLK, HJL, IT).

Funding

The development and coordination of the Delphi survey has been funded with the research budgets of Istituto Giannina Gaslini; no external entity such as pharmaceutical companies has been involved at any stage of the project.

Competing interests

Authors:

For EBC, MG, AG, DLK, HJL, IT: Nothing to disclose for this manuscript.

NR received honoraria for consultancy of speaker's bureau from the following pharmaceutical companies since last 5 years: Abbott, AbbVie, Amgen, Biogenidec, Astellas, Alter, AstraZeneca, Baxalta Biosimilars, Boehringer, BMS, CD-Pharma, Celgene, CrescendoBio, EMD Serono, Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, Rewind Arms, R-Pharma, Sanofi Aventis, Servier, Sinergie, Takeda, Vertex, UCB Biosciences GmbH.

The Gaslini Hospital, which is the public Hospital where NR works as full time public employee, has received contributions from the following industries:

Abbott, BMS, "Francesco Angelini", GlaxoSmithKline (GSK), Hoffman-La Roche, Italfarmaco, Janssen, Novartis, Pfizer, Sanofi Aventis, Schwarz Biosciences, Sobi,

1
2
3
4
5
6 Xoma, Wyeth. This money has been reinvested for the research activities of the
7 hospital in a fully independent manner without any commitment with third parties.
8
9

10 **Additional participants to the Delphi study**

11
12 Ivona Aksentijevich, Jordi Anton, Juan I Arostegui, Karyl S. Barron, Luca Cantarini,
13 Fatma Dedeoglu, Erkan Demirkaya, Joost Frenkel, Veronique Hentgen, Michael
14 Hofer, Isabelle Koné-Paut, Jasmin B. Kuemmerle-Deschner, Avi Livneh, Alberto
15 Martini, Laura Obici, Seza Ozen, Dorota Rowczenio, Ricardo Russo, Yael Shinar,
16 Natasa Toplak, Marielle van Gijn have no conflicts of interest to declare.

17
18 Dirk Foell has received grant support from Novartis and Pfizer, and honoraria from
19 Sobi, Chugai-Roche, Novartis and Pfizer

20 Philip J. Hashkes has acted as consultant and speaker for Novartis and consultant
21 for Neovii.

22 Yosef Uziel has received Grant / Research Support from Novartis, has acted as
23 consultant for Novartis, and has received speaker's bureau from Abbvie, Neopharm,
24 Novartis and Roche.

25 Tilmann Kallinich has received speaker's bureau from Novartis, Sobi and Roche, and
26 a research grant from Novartis.

27 Ronald Laxer has acted as consultant for Lilly and Sanofi
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

References

1. Beil M, Ben-Chetrit E. Taxonomy of auto-inflammatory diseases: time to consider changing some names. *Clin Exp Rheumatol* 2013;31(3 Suppl 77):3-5.
2. Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. *Nat Immunol* 2017; 18: 832– 842 .
3. International FMF Consortium: Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. *Cell* 1997; 90:797-807.
4. French FMF Consortium: A candidate gene for familial Mediterranean fever. *Nat Genet* 1997;17:25-31.
5. McDermott M F, Aksentijevich I, Galon J, et al. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes *Cell* 1999;97: 133 –144
6. Siegal S (1945). "Benign paroxysmal peritonitis". *Ann Intern Med* 1945; 23 (2): 234 – 247
7. Reiman HA . "Periodic disease. Probable syndrome including periodic fever, benign paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia". *J Am Med Assoc* 1948; 136 (4): 239 – 244.
8. Cattan R, Mamou H. 14 Cases of periodic disease, 8 of which are complicated by kidney diseases. *Bull Mem Soc Med Hop Paris*. 1951;67:1104–1110
9. Heller H, Sohar E, Sherf L. Familial Mediterranean fever. *AMA Arch Intern Med* 1958;102:50 – 71
10. Ehrenfeld E N, Eliakim M, Rachmilewitz M, Recurrent polyserositis (familial mediterranean fever; Periodic disease): A report of fifty-five cases. *The Am Journal of Med* 1961; 3: 107-123
11. Saatci U, Ozen S, Bakkaloglu A, et al. Familial Mediterranean fever: a misnomer? *Lancet*. 1994;343(8895):485.
12. Masters SL, Lagou V , Jéru I et al. Pyrin Associated Autoinflammation with Neutrophilic Dermatitis (PAAND), Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. *Science Translational Medicine* 2016; 8 : 332-345
13. Williamson L M, Hull D, Mehta R, et al. Familial hibernian fever. *Quart J Med*, 1982, 51; 469 –480

14. Mulley J, Saar K, Hewitt G et al.. Gene localization for an autosomal dominant familial periodic fever to 12p13 *Am J Hum Genet* 1998; 62: 884–889
15. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. *Nat Genet* 1999; 22 : 178 – 181.
16. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. *Nat Genet* 1999; 22 (2): 175 –177.
17. van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. *Lancet* 1984; 1 (8386): 1087–1090.
18. Frenkel J, Houten SM, Waterham HR et al. Mevalonate kinase deficiency and Dutch type periodic fever. *Clin Exp Rheumatol.* 2000;18(4):525-532
19. Prieur AM, Griscelli C Arthropathy with rash, chronic meningitis, neurological changes and arthritis. *J Pediatr* 1981; 99: 79-83.
20. Muckle TJ. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. *Quart J Med.* 1962 ; 31: 235 – 248
21. Kile, R. L., Rusk, H. A. A case of cold urticaria with unusual family history. *J Am Med Assoc* 1940; 114: 1067-1068
22. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat Genet* 2001; 29 (3): 301–305
23. Blau EB. Familial granulomatous arthritis, iritis, and rash. *Pediatr.* 1985;107(5):689 - 693
24. James DG. A comparison of Blau's syndrome and sarcoidosis. *Sarcoidosis.* 1994;11(2):100-1
25. McGovern DP, van Heel DA, Ahmad T, et al. NOD2 (CARD15), the first susceptibility gene for Crohn's disease. *Gut.* 2001;49:752–754.
26. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1–receptor antagonist. *N Engl J Med* 2009; 360: 2426–2437.
27. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. *N Engl J Med* 2011;365 (7):620–628
28. Majeed, H; Kalaawi, M; Mohanty, D et al. Congenital dyserythropoietic anemia and chronic recurrent multifocal

- osteomyelitis in three related children and the association with Sweet syndrome in two siblings. *J Pediatrics* 1989;115: 730 – 734.
29. Ferguson P J, Chen S, Tayeh M K, et al.. Homozygous mutations in *LPIN2* are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome) *J Med Genet* 2005;42:551–557.
30. Keipert JA, Campbell PE. Recurrent hyperostosis of the clavicles: an undiagnosed syndrome. *Aust Paediatr J* 1970; 6 (1):97–104.
31. Giedion A, Holthusen W, Masel LF, et al. Subacute and chronic “symmetrical” osteomyelitis. *Ann Radiol (Paris)* 1972;15(3):329 – 342
32. Fuchs-Telem D, Sarig O, van Steensel M A M et al. Familial Pityriasis Rubra Pilaris Is Caused by Mutations in *CARD14* *Am J Hum Genet* 2012 ;91: 163–170
33. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in *CARD14*. *Am J Hum Genet* 2012;90:784-795
34. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med.* 2009;361(21):2033 – 2045.
35. Glocker EO, Frede N, Perro M, et al. Infant colitis-it's in the genes. *Lancet.* 2010;376 (9748):1272
36. Jeru I, Duquesnoy P, Fernandes-Alnemri T et al. Mutations in *NALP2* cause hereditary periodic fever syndromes. *PNAS*, 2008 :105 (5): 1614 –1619
37. Lindor NM, Arsenaault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. *Mayo Clin Proc* 1997;72:611–615
38. Wise CA, Gillum JD, Seidman CE, et al. Mutations in *CD2BP1* disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. *Hum. Mol. Genet.* 2002;11:961–969
39. Liu Y, Ramot Y, Torrello A et al: Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. *Arthritis Rheum.* 2012; 64: 895-907
40. Agarwal AK, Xing C, DeMartino GN et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. *Am J Hum Genet* 2010; 87: 866-872
41. Arima K, Kinoshita A, Mishima H, et al: Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. *Proc Natl Acad Sci U S A.* 2011, 108: 14914 - 14919

Formatted: Italian (Italy)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
42. Schnitzler L. Lésions urticariennes chroniques permanentes (érythème pétaoloïde?) Cas cliniques No 46 B, *J Dermatol Angers* 1972 ; Abstract 46
43. Tyson T K, Edwards F L. Periodic fever syndrome in children. *J Pediatr* 1999; 135: 1– 5
44. Marshall GS, Edwards KM, Butler J, et al. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. *J Pediatr* 1987;110:43 - 46
45. Ombrello M J, Remmers E F, Sun G et al. Cold Urticaria, Immunodeficiency, and Autoimmunity Related to *PLCG2* Deletions *N Engl J Med* 2012; 366:330-338
46. Wang K, Kim C, Bradfield J, et al. Whole-genome DNA/RNA sequencing identifies truncating mutations in *RBCK1* in a novel Mendelian disease with neuromuscular and cardiac involvement. *Genome Medicine* 2013; 5 (7): 67-74
47. Ueki Y, Tiziani V, Santanna C. et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. *Nat Genet* 2001;28:125 –126
48. Jones, W. A. Familial Multilocular Cystic Disease of the Jaws. *American J Cancer* 1933;17 (4): 946-950
49. Jones, W. A. Gerrie, J. Pritchard, J. Cherubism-familial fibrous dysplasia of the jaws. *J bone joint surgery* 1950;32 (3): 334–347.
50. Jaffe H L. Giant cell reparative granuloma traumatic bone cyst, fibrous (fibro-osseous) dysplasia of jaw bones. *Oral Surg* 1953;6:159-175
51. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigms and nomenclature. *J Med Genet* 2013;50:349–359
52. Ruperto N, Meiorin S, Iusan S M, et al. Consensus procedures and their role in pediatric rheumatology. *Curr rheumatol reports* 2008;10:142-146.
53. Pill J, The Delphi method: Substance, context, a critique and an annotated bibliography. *Socio-Economic Planning Sciences*. 1971; 5: 57-71
54. Toplak N, Frenkel J, Ozen S et al. for the Paediatric Rheumatology International Trials Organisation (PRINTO). Eurotraps and Eurofever Projects. An International registry on Autoinflammatory diseases: the Eurofever experience. *Ann Rheum Dis* 2012;71:1177-1182.
55. Federici S, Sormani M, Ozen S et al for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project. Evidence-based provisional clinical classification criteria for

Formatted: Italian (Italy)

- 1
2
3
4
5
6 autoinflammatory periodic fevers. *Ann Rheum Dis* 2015; 2015;74:799
7 – 805
- 8
9 56. Ruperto N, Martini A, for the Paediatric Rheumatology International
10 Trials Organisation (PRINTO). Networking in pediatrics: the example
11 of the Pediatric Rheumatology International Trials Organisation
12 (PRINTO). *Archives Dis Child* 2011; 96:596 - 601.
- 13
14 57. McGonagle D, McDermott MF (2006) A proposed classification of the
15 immunological diseases. *PLoS Med* 2006; 3 (8): e297:1242-1248
- 16
17 58. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory
18 disease reloaded: a clinical perspective. *Cell* 2010;140:784–790.
- 19
20 59. Grateau G, Hentgen V, Stojanovic KS, et al. How should we approach
21 classification of autoinflammatory diseases? *Nat Rev Rheumatol*
22 2013; 9: 624-629
- 23
24 60. Wekell P, Berg S, Karlsson A, et al. Towards an inclusive, congruent,
25 and precise definition of autoinflammatory diseases. *Frontiers in*
26 *Immunol.* 2017, Vol 8 Article 497.
- 27
28 61. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigm
29 and nomenclature. *J Med Genet* 2013; 50:349-359.
- 30
31 62. de Jesus A, Canna S W, Liu Y, Goldbach-Mansky R., Molecular
32 Mechanisms in Genetically Defined Autoinflammatory Diseases:
33 Disorders of Amplified Danger Signaling. *Annu Rev Immunol.* 2015 ;
34 33: 823–874.
- 35
36 63. Milner J D. PLAID: A syndrome of complex patterns of disease and
37 unique phenotypes. *J Clin Immunol.* 2015; 35: 527– 530.
- 38
39
40 64. Rodero MP, Yanick J. Crow J Y, Type I interferon–mediated
41 monogenic autoinflammation: The type I interferonopathies, a
42 conceptual overview *J Exp Med* 2016; 213: 2527–2538
- 43
44 3
- 45 65. Shimizu M, Tone Y, Toga A, et al. Colchicine-responsive chronic
46 recurrent multifocal osteomyelitis with MEFV mutations: a variant of
47 familialMediterranean fever? *Rheumatology*, 2010; 49:2221– 2223
- 48
49 66. Ben-Chetrit E, Ozdogan H. Can we make a diagnosis of
50 autoinflammatory diseases based upon clinical features only? *Clin Exp*
51 *Rheumatol* 2017, (35 Suppl) 108(6):16-18.
- 52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 67. Prietsch, V., Mayatepek, E., Krastel, H., et al. Mevalonate kinase
7 deficiency: enlarging the clinical and biochemical spectrum. *Pediatrics*
8 111: 258-261, 2003
- 9
10 68. Hofmann S R, Kapplusch F, Girschick H J et al. Chronic Recurrent
11 Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and
12 Treatment. *Curr Osteoporos Rep.* 2017; 15(6): 542–554
- 13
14 69. de Koning H D, van Gijn M E, Stoffels M, Myeloid lineage–restricted
15 somatic mosaicism of *NLRP3* mutations in patients with variant
16 Schnitzler syndrome. *J Allergy Clin Immunol* 2015;135: 561-564.
- 17
18 70. Peckham D, Scambler T, Savic S, et al. The burgeoning field of
19 innate immune-mediated disease and autoinflammation. *J Pathol*
20 2017; 241: 123 –139.
- 21
22 71. Artis D, Spits H. The biology of innate lymphoid cells, *Nature* 2015;
23 517:293-301
- 24
25 72. Holzinger D, Fassl S K, de Jager W, et al, Single amino acid charge
26 switch defines clinically distinct proline-serine-threonine phosphatase-
27 interacting protein 1 (PSTPIP1)–associated inflammatory diseases *J*
28 *Allegy clin immunol* 2015;136:1337-1345
- 29
30 73. Karacan I, Uğurlu S, Tolun A, et al. Other autoinflammatory disease
31 genes in a FMF-prevalent population: A homozygous missense MVK
32 mutation and a novel heterozygous TNFRSF1A mutation in two
33 different Turkish families with clinical FMF. *Clin Exp Rheumatol* 2017,
34 35 Suppl 108(6):75-81
- 35
36 74. Brehm A, Liu Y, Sheikh A et al. Additive loss-of-function proteasome
37 subunit mutations in CANDLER/PRAAS patients promote type I IFN
38 production. *J clin Invest* 2015;125:4196 – 4211
- 39
40 75. Rigaud S, Fondanèche MC, Lambert N et al. XIAP deficiency in
41 humans causes an X-linked lymphoproliferative syndrome. *Nature.*
42 2006 ;444:110-4.
43
44
45
46
47
48
49
50
51
52
53
54

Glossary - Abbreviations

AGS - Aicardi-Goutières Syndrome

AIDs - Autoinflammatory diseases

AIMDs - Autoimmune diseases

ALPS - Autoimmune lymphoproliferative syndrome

APR - Acute phase reactant

CANDLE - Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome

CAPS - Cryopyrin-associated periodic fever syndrome

CARD - Caspase recruitment domain family member

CINCA- Chronic infantile neurologic, cutaneous and articular syndrome

CNO - Chronic non-bacterial osteomyelitis

CRMO -Chronic recurrent multifocal osteomyelitis

ADA2 - adenosine deaminase 2

DIRA - Deficiency of the interleukin 1 receptor antagonist

DITRA - Deficiency of the interleukin 36 receptor antagonist

FCAS - Familial cold autoinflammatory syndrome

FMF - Familial Mediterranean fever

HIDS - Hyper-IgD with periodic fever syndrome

HOIL -1 - Heme - oxidised IRP2 ubiquitin ligase 1

IBD - Inflammatory bowel disease

ISSAID - International society for systemic autoinflammatory diseases

JMP - Joint contractures, muscle atrophy, microcytic anemia and panniculitis-induced lipodystrophy.

LOGRUF - Late onset gammopathy with recurrent urticarial and fever

MEFV - Mediterranean fever

MK- Mevalonate kinase

1
2
3
4
5
6 **MKD** - Mevalonate kinase deficiency
7 **MVK** - Mevalonate kinase
8
9 **MWS** - Muckle-Wells syndrome;
10
11 **NALP 12**- NACHT, LRR and PYD domains-containing protein 1
12
13 **NGS** - New generation sequencing
14
15 **NLR** - NOD-like receptor
16
17 **NLRC4** - NOD-like receptor with CARD containing 4
18
19 **NLRP** - NOD-like receptor with LRR (Leucine rich repeat), and PYD domain;
20
21 **NOD** - Nucleotide-binding oligomerization domain;
22
23 **NOMID** - Neonatal onset multisystem inflammatory disease
24
25 **PAAND** - Pyrin-associated autoinflammation with neutrophilic dermatosis
26
27 **PAMI** - *PSTPIP1*-associated myeloid-related proteinemia inflammatory syndrome
28
29 **PAPA** - *PSTPIP1* arthritis, pyoderma gangrenosum, and acne
30
31 **PFAPA**: Periodic fever, aphthous stomatitis, pharyngitis and adenitis
32
33 **PLD** - *PLCG2* dysregulation
34
35 **PLAID** - *PLCG2*-associated antibody deficiency and immune dysregulation
36
37 **PLCG2** - Phospholipase C γ 2
38
39 **POMP** - proteasome maturation protein
40
41 **PRINTO** - Pediatric rheumatology international trials organization
42
43 **PRAAS** - Proteasome associated autoinflammatory syndrome
44
45 **PSMB 3-4,8-9** - Proteasome Subunit, β -type, 3,4,8,9
46
47 **PSTPIP1** - proline serine threonine phosphatase-interacting protein 1
48
49 **-SAPHO** - synovitis, acne, pustulosis, hyperostosis, and osteitis
50
51 **SDCM** - SH3BP2 deficiency with multilocular cystic disease of the mandibles.
52
53 **SH3BP2** - SH3 Domain Binding Protein2
54
55 **SAP** - SLAM - associated protein
56
57 **SLE** - systemic lupus erythematosus
58
59 **TNF** - Tumor necrosis factor
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TNFRSF1A - Tumor necrosis factor receptor super family 1A

TRAPS - TNF-receptor-associated periodic syndrome

XIAP - X-linked Inhibitor of Apoptosis

Confidential: For Review




Table 1. Current name of the disorder (in bold) and additional names (normal characters) derived from the literature. The last column reports the proposed nomenclature for the AIDs as results of the consensus process.

Current name of the disorder and additional names	Proposed nomenclature
<p>CAPS - Cryopyrin-associated periodic fever syndrome [20]</p> <p>CINCA - Chronic infantile neurological, cutaneous and articular syndrome [17], NOMID - Neonatal onset multisystem inflammatory disease</p> <p>MWS - Muckle-Wells syndrome [18]</p> <p>FCAS - Familial cold autoinflammatory syndrome [19]</p>	<p><i>NLRP3</i>-associated autoinflammatory disease (<i>NLRP3</i>-AID)</p> <p>Severe</p> <p>Moderate</p> <p>Mild</p>
<p><i>CARD14</i>-associated disease</p> <p>PRP - Familial Pityriasis rubrapilaris [30]</p> <p>CAMPS - <i>CARD14</i>-mediated pustular psoriasis [31]</p> <p>Cherubism [45]</p> <p>Familial Multilocular Cystic Disease of the Jaws [46]</p> <p>Cherubism--familial fibrous dysplasia of the jaws [47]</p> <p>CGCL - Central giant cell lesion [48]</p>	<p><i>CARD14</i>-associated psoriasis</p> <p><i>SH3BP2</i> deficiency with multi locular cystic disease of the mandibles (SDCM)</p>
<p>CRMO - Chronic recurrent multifocal osteomyelitis [29]</p> <p>Majeed syndrome [26],</p> <p>Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis [27]</p> <p>LIPIN2-associated disease [28]</p>	<p>Chronic non-bacterial osteomyelitis (CNO) - (when the gene is known it should be added)</p> <p><i>LPIN2</i>-CNO</p>
<p>DIRA – Deficiency of the IL-1 receptor antagonist [24]</p>	<p>(No change)</p>
<p>DITRA - Deficiency of the IL-36 receptor antagonist [25]</p>	<p>(No change)</p>
<p>FCAS2 – Familial cold autoinflammatory syndrome 2 [36]</p> <p>Guadeloupe fever, NALP12 periodic fever</p>	<p><i>NLRP12</i>-associated autoinflammatory disease (<i>NLRP12</i>-AID)</p>

Current name of the disorder and additional names	Proposed nomenclature
syndrome [36]	Pyrin-associated autoinflammatory disease (PAAD)
FMF - Familial Mediterranean fever (FMF)[7] Benign paroxysmal peritonitis [4] , Periodic disease [5], Armenian disease, Periodic disease "Maladie periodique" [6], Familial Mediterranean fever (FMF) [7], Recurrent polyserositis [8], Familial paroxysmal polyserositis [9]	(No change)
PAAND - Pyrin-associated autoinflammation with neutrophilic dermatosis [10]	(No change)
JMP Joint contractures, Muscle atrophy, Microcytic Anemia and Panniculitis Induced Lipodystrophy [38], Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome [37], Nakajo-Nishimura Syndrome (NNS) [39]	Proteasome-associated autoinflammatory syndrome (PRAAS) <i>PSMB8</i>-PRAAS, <i>PSMB4/PSMB9</i>-PRAAS, <i>PSMB4/PSMB9</i>-PRAAS, <i>PSMA3/PSMB8</i>-PRAAS
HIDS - Hyper IgD syndrome [15] Mevalonic aciduria (67) Mevalonate kinase disease (Deficiency) [13, 14] Dutch type periodic fever [16]	Mevalonate kinase deficiency (MKD) Mild Severe (Add porokeratosis or retinitis pigmentosa when present)
IL-10 Deficiency IBD - IL-10R-associated very early [32] Infantile colitis [33]	IL-10 deficiency-associated Inflammatory bowel disease
<i>NOD2</i> <i>CARD15</i>-Associated disease Blau syndrome [21], Early onset sarcoidosis [22], Familial Crohn's disease [23]	<i>NOD2</i>-associated granulomatous disease (Optional: add Blau syndrome or IBD according to the main clinical features)
PAPA / Pyogenic Arthritis, Pyoderma gangrenosum, and Acne syndrome [35]	<i>PSTPIP1</i>-associated arthritis, pyoderma gangrenosum, and acne (PAPA)

Current name of the disorder and additional names	Proposed nomenclature
PFAPA - Periodic fever, aphthous stomatitis, pharyngitis and adenitis Periodic fever, aphthous stomatitis, pharyngitis and adenitis or periodic fever aphthous pharyngitis and cervical adenopathy [41] Marshall's syndrome [42]	(No change)
Schnitzler syndrome [40] PUPAP - Periodic fever with urticaria and paraprotein	(No change)
TRAPS - TNF receptor-associated periodic fever syndrome[3] Familial Hibernian fever [11] Familial autosomal dominant periodic fever [12]	(No change)

Table 2. Results from the Delphi questionnaires for consensus on nomenclature

Definition or Disease	Group of AIDs experts consensus (N=26)
Definition	
Autoinflammatory diseases are clinical disorders caused by defect(s) or dysregulation of the innate immune system, characterized by recurrent or continuous inflammation (elevated APR) and by the lack of a <i>primary</i> pathogenic role of the adaptive immune system (auto - reactive T-cells or autoantibody production).	87%
Final names proposed for the AIDs	
<i>CARD14</i> -associated psoriasis	91%
CNO: Chronic non-bacterial osteomyelitis	87%
DIRA: Deficiency of the IL-1 receptor antagonist	96%
DITRA: Deficiency of the IL-36 receptor antagonist	96%
IL-10 deficiency-associated inflammatory bowel diseases	83%
PAAD: Pyrin-associated autoinflammatory disease: FMF, PAAND	88%
MKD: Mevalonate kinase deficiency	87%
<i>NLRP3</i> -AID – <i>NLRP3</i> -associated autoinflammatory disease	88%
<i>NLRP12</i> -AID – <i>NLRP12</i> -associated autoinflammatory disease	88%
<i>NOD2</i> -associated granulomatous diseases	83%
PAPA: <i>PSTPIP1</i> -associated arthritis, pyoderma gangrenosum and acne	87%
PFAPA: Periodic fever, aphthous stomatitis, pharyngitis and adenitis	83%
PRAAS : Proteasome-associated autoinflammatory syndrome	84%
Schnitzler syndrome	87%
SDCM - <i>SH3BP2</i> deficiency with multilocular cystic disease of the mandibles	94%
TRAPS - TNF receptor-associated periodic fever syndrome	83%

Table 3. Recommendations for naming AIDs

1. Try not to change wherever the name is appropriate.
2. Avoid names of persons or geographical spread of disease (eponyms)
3. Include the genetic basis (name of the gene) of the disease where it is known (prefer the name of the gene over the name of the encoded protein unless the name of the gene is not accurate or meaningless)
4. Include key clinical features where appropriate
5. Shorten the name as much as possible
6. Choose a name that is as clear as possible
7. In diseases where our knowledge about the pathogenesis is still limited, leave the previous name (PFAPA)
8. In diseases with different phenotypes but mutations in the same gene, use a general "roof" name with subtypes (PAAD, NOD2).
9. When the clinical features seemed to be "continuous" give a general name ("roof" name) and classify the various presentations according to their phenotypic severity (*NLRP3-AID*, *MKD*).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends to figure

Figure 1

The group of diseases associated with *MEFV* sequence alterations. The "roof" name is a general name whereas the subtypes are more specific and meaningful.

Confidential: For Review

